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Abstract 
Mitochondrial membranes have a diverse structure composed of numerous 
phospholipids, including cardiolipin (CL). Several processes are required to synthesize· 
and remodel CL. We previously demonstrated that CL content increases with chronic 
muscle use, and decreases with denervation. To investigate the mechanisms underlying 
these effects, we measured the m.RNA expression of CL metabolism enzymes, including 
1) CL synthesis enzymes Cardiolipin synthase (CLS) and CTP:PA-cytidylyltransferase-1 
(CDS-1 ); 2) remodelling enzymes Tafazzin (Taz) and Acyl-CoA:lysocardiolipin 
acyltransferase-1 (ALCATl); and 3) outer membrane CL enzymes, Mitochondrial 
phospholipase D (MitoPLD) and phospholipid scramblase 3 (Plscr3). We found that the 
transcriptional coactivator PGC-la regulates them.RNA levels of CDS-1 and ALCATl, 
thus playing a role in both CL synthesis and remodelling. We found that all three enzyme 
categories were altered by our conditions, but unaffected by age, suggesting that chronic 
muscle use and disuse have divergent influences on the expression of mRNAs encoding 
enzymes involved in CL metabolism. 
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Literature Review 
1.1 The Phospholipid Cardiolipin 
1.1.1 Introduction 
Since the time of Singer and Nicholson in the 1960s, the fluid mosaic model of 
membranes has drawn scientists to explore the dynamic world of proteins and 
phospholipids that encapsulate the cell, as well as the organelles within it. The 
phospholipid cardiolipin (CL) was first discovered during World War II by a female 
scientist named Mary Pangborn (100). She initially isolated it from bovine heart tissue, 
hence the name's cardio- prefix. In mammals, CL is present in all mitochondria-
containing tissues, and is most abundantly expressed in the heart. CL is exclusive to both 
the inner (IMM) and outer mitochondrial membranes (OMM) and has often been called 
"the glue that holds the electron transport chain (ETC) together" (120). Since then, the 
phospholipid has been found to play numerous other roles within the cell, including the 
optimization of ETC function and the execution of mitochondrially-mediated apoptosis. 
1.1.2 Structure 
CL is a dimeric molecule held together by a glycerol bridge, and is composed of 
two phosphate heads, four fatty acid (FA) tails and a total of three glycerol groups (66). 
Due to its dimeric structure and mainly unsaturated FA composition, the molecular 
structure of CL takes on a cone-like, rather than cylindrical shape, often seen in 
monomeric phospholipids (Fig. lA and lB). It is therefore non-bilayer forming and helps 
to create the peaks and troughs of mitochondrial cristae (101; 113). It is also important to 
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Figure 1. Cardiolipin (CL) structure and localization. 
(A) Bilayer forming, monomeric phospholipids, such as phosphatidylcholine and 
phosphatidylserine. (B) Non-bilayer forming, dimeric phospholipid CL. (C) The 
localization of CL and its metabolism enzymes. CL de novo biosynthesis enzymes are 
rectangular, while CL transport and remodelling enzymes are oval. MitoPLD, 
mitochondrial phospholipase D; Plscr3, phospholipid scramblase 3; CDS-I, CTP:PA 
cytidylyltransferase; POPS, phosphatidylglycerol-phosphate synthase; CLS, cardiolipin 
synthase; ALCAT-1, lysocardiolipin acyltransferase; Taz, tafazzin; MLCL AT, 
monolysocardiolipin acetyltransferase; TOM, translocase of the outer mitochondrial 
membrane; MAM, mitochondrial-associated membranes. 
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note that the FA composition of CL varies across different species and tissue types. In 
bacteria and yeast, the CL FA composition varies from 14-18 carbons in length, while 
oxidative tissue cells in mammals almost exclusively express 18-carbon FA, either the 
oleic (18:1) or linoleic (18:2) type (44). A prime example of this trend is found in bovine 
cardiac muscle, where 80% of CL is tetralinoleic (61). The kinks in the unsaturated FAs 
of tetralinoleic CL contribute to its non-bilayer structure (7). This is particularly 
beneficial for tissues that contain mitochondria with condensed cristae, such as muscle, 
which have been shown to have a higher proportion of tetralinoleic CL when compared to 
non-condensed cristae tissues, such as liver (100). It is also important to note that rats· 
exposed to altered FA diets revealed that CL is most ·resistant to FA composition 
alterations, relative to other phospholipids (118). This tightly controlled FA makeup is 
also crucial for allowing CL to bind to membrane-embedded structures, such as those of 
the ETC, which helps maintain their structure, alignment and function (100). CL FA 
alterations have been shown to inhibit CL from enhancing the enzymatic activity of the 
proteins it binds, thus resulting in a detrimental effect on the cell's function (69; 100). 
1.1.3 Function 
To call CL the "glue" of the ETC is only appropriate when it is located in the 
IMM. As we will see, the role that this phospholipid plays in the cell is highly dependent 
on its location within it. 
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1.1.3 .1 Electron Transport Chain Stabilization 
In the IMM, CL ionically.binds to, and stabilizes complexes that make up the ETC, 
including cytochrome c and complexes I, III, IV and V (22). Not only does CL help keep 
the ETC components aligned fo ensure proper electron transfer, it also aids in the stability 
of dimetjc secondary structures found often in the ETC (94; 120). The fourth complex of 
the ETC is called cytochrome c oxidase (COX), and it binds four CL molecules. COX 
and CL s~em to have a symbiotic relationship; CL increases the enzymatic activity of 
COX, while COX stabilizes CL's orientation within the membrane (32; 94). CL does not 
exclusively bind to enzymes present in the ETC. For example, it binds to· the adenine 
nucleotide translocator (ANT), the dimeric structure of which binds six CL molecules so 
tightly that only denaturing conditions can pry them apart, which results in the complete 
loss of ANT function (10). Despite the fact that the CL molecules bound to these 
structures are tetralinoleic, it was shown that nei~er the hydrogenation of the double 
bonds, nor the removal of one FA by phospholipase Az, is able to dissociate CL from 
ANT, although a reduction in the enzymatic activity of ANT was observed (11). 
1.1.3 .2 Role in Apoptosis 
The location of multiple phospholipids has been found to be crucial for apoptotic 
signalling within the cell (34; 72). For instance, phosphatidylserine (PS) is found within 
the plasma membrane, and is transported from the inner to the outer surface of the 
membrane during apoptosis. Macrophages are then able to· recognize the externalized PS, 
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leading to the consumption of that apoptotic cell via phagocytosis (34 ). Within the 
mitochondria, CL is transferred from the IMM to the OMM to act as a binding site for 
truncated B-cell lymphoma 2 interacting domain (tBid), a proapoptotic protein (81 ). This 
interaction allows tBid to localize to the mitochondria and release cytochrome c to induce 
mitochondrially-mediated apoptosis (22; 37; 81). More specifically, tBid activates the 
proteins Bax and Bak to form channels on the OMM, through which cytochrome c can be 
released (81 ). CL on the IMM also takes part in this process, as CL-cytochrome c bonds 
must first be broken to release cytochrome c into the intermembrane space (23 ). This 
dissociation occurs via the remodelling of CL' s F As. During apoptotic conditions, oleic 
and linoleic FAs are replaced by longer, more unsaturated F As (69). This FA composition 
not only inhibits CL-protein interaction directly, but makes CL more susceptible to 
damage by reactive oxygen species (ROS), in a process called peroxidation which 
contributes further to CL-protein dissociation (23; 59; 84). It is therefore not surprising 
that CL is the only phospholipid that experiences early peroxidation during apoptosis (59). 
1.1.4 Localization 
1.1.4.1 Inner and Outer Mitochondrial Membranes 
While CL is found only in mitochondria, its distribution within the organelle is 
tightly regulated (Fig. 1 C). Originally thought to be exclusive to the IMM, CL has been 
found to cluster at the mitochondrial contact point regions, where the IMM and OMMs 
meet, as well as in the OMM itself (7; 60). In studies that split the two membranes, --90% 
of CL was found in the IM~, with the remaining --10% residing in the OMM (39). 
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1.1 A.2 Phospholipid scramblase 3 
The protein family of scrambl~es is responsible for the bidirectional transport of 
phospholipids (29). An important member of this protein family, phospholipid scramblase 
3 (Plscr3), is embedded within the mitochondrial contact sites and acts to transfer CL 
between the IMM and OMMs (41; 72). Plscr3 is ATP-independent and is activated both 
by phosphorylation via Protein Kinase C-o as well as the binding of calcium (72; 73). As 
discussed above, the transport of CL to the OMM is an integral part of mitochondrially-
mediated apoptosis, making the transpot;ter Plscr3 central to this process ( 41 ). While if is 
known Plscr3 transfers CL in a bidirectional manner, what factors influence the direction 
of the enzyme's function have been disputed. This d~bate was brought about when the 
overexpression of Plscr3 led to increased levels of OMM CL, along with an increased 
apoptotic susceptibility, while Plscr3 knockdown led to decreased OMM CL and reduced 
apoptotic susceptibility (73; 114 ). Which conditions determine the direction of Plscr3 's 
transport of CL remains to be determined. It is also noteworthy that the overexpression of 
Plscr3 led to decreased mitochondrial respiration and ATP levels, perhaps due to a drop 
in CL levels in the IMM (73). 
1.1.4.3 Mitochondrial Phospholipase D 
Mitochondrial phospholipase D (MitoPLD) is the sixth member of the 
Phospholipase D family (24 ). It is a dimeric ~nzyme found on the outer surface of the 
OMM that acts on adjacent mitochondria to cleave CL into phosphatidic acid (PA), the 
monomeric form of CL (14; 52). PA on the OMM has been shown to play a role in 
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mitochondrial fission and fusion, either by enhancing fusion via the stabilization of 
mitofusin-2 (Mfn-2, an OMM fusion protein), or by being converted to diacylglycerol 
(DAG) by the phosphatase Lipinl, which promotes fission (18; 24; 52). Thus, MitoPLD 
and Lipinl have opposing effects on mitochondrial dynamics, and both work through 
phospholipid messengers (52). MitoPLD's influence on mitochondrial dynamics was first 
discovered when its overexpression was shown to lead to aggregated mitochondria, while 
MitoPLD knockdown cells experienced mitochondrial fragmentation. It is important to 
note that Mfn-2 is necessary to anchor two mitochondria together, only then can 
MitoPLD exert its effects (24). 
1.1.5 Synthesis 
Mitochondria contain a mosaic of different phospholipids. Phosphatidylcholine' 
(PC) and phosphatidylethanolamine (PE) are the most abundant. They make up 40% and 
30% of the organelle's total phospholipid content, respectively (26). The endoplasmic 
reticulum (ER, or sarcoplasmic in muscle, SR) is responsible for the production of these 
two major phospholipids, along with PA (33). The synthesis of CL, however, occurs in 
the mitochondria and begins like all phospholipid production; through the Kennedy 
pathway ( 62). The mitochondria' s source of PA comes from two pools: from the ER and 
from direct production on the OMM ( 42). The transfer of phospholipids from the ER to 
the mitochondria is facilitated by structures called mitochondrial-associated membranes, 
or MAMs (mitochondrial-associated membranes; Fig.1 C). Once PA is available, all of the 
downstream enzymes necessary for its conversion into CL are found in the IMM (35; 50). 
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1.1.5 .1 CDS-1, The Rate Limiting Enzyme 
~e use of pulse-chase analyses in isolated rat hearts has led to the discovery that 
CTP:PA cytidylyltransferase (CDS) is the rate-limiting enzyme of de novo CL 
biosynthesis (39). It is responsible for facilitating a reaction that converts PA into 
cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG) (100). The mRNA levels ·of this 
gene are most abundant in mammalian testes, with relatively low levels in cardiac and 
skeletal muscle (53; 82). CDS is found on both the matrix side of the IMM, where it 
contributes to CL production, as well as on the cytoplasmic side of the ER, where it helps 
produces phosphatidylinositol. There are two known genes that encode CDS in mammals, 
CDS-1 and CDS-2, but it is important to note that only the mRNA levels of the former 
match the enzymatic activity of CDS in isolated mitochondrial fractions (53; 82; 96). 
CDS-1 is therefore thought to play a larger role in the production of CL within the 
mito,chondria, relative to CDS-2 (96). 
1.1.5.2 Cardiolipin Synthase, The Final Synthesis Enzyme 
The terminal step in the CL de novo biosynthesis pathway involves the fusion of 
phosphatidylglycerol (PG) and CDP-DG, and is executed by the matrix protein 
cardiolipin synthase (CLS). CLS is located on the inner leaflet of the IMM and its mRNA 
expression in mammals is most abundant in heart and skeletal muscle (20; 79; 98). It has 
been shown that the FA composition of the CL precursors PG and CDP-DG are different 
from those of functional CL molecules (95). This is because CLS has been shown to lack 
specificity for the FA chains attached to its phospholipid substrates ( 49). Thus, it was 
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later discovered that CL FA remodelling follows the production of CL. This dynamic 
pro~ess will be discussed later in more detail. The enzymatic activity of CLS has been 
shown to be upregulated by thyroid hormone, as well as the presence of the CL molecule 
itself (17; 99). It was f~und that the mRNA expression of CLS does not correlate with its 
enzymatic activity in models of inflammation (80). In striated muscle, however, a 
correlation was found between CLS mRNA and enzymatic activity (96). It is. also 
noteworthy that increases in CLS activity were shown to upregulate CL content in 
bacteria (43). 
1.1.6 Cardiolipin Remodelling 
Since PG and CDP-DG, the precursors of CL, have different FA compositions 
than CL, post-synthesis remodelling of CL must occur (Fig.2). Like many phospholipids, 
CL undergoes processes that are part of the Lands' Cycle, a pathway that specifically 
remodels FA structures on phospholipids (65; 95). A single FA is initially removed from 
CL to produce monolyso-CL (MLCL), via phospholipase A2 (14). FAs of desired 
confirmation are then attached to the MLCL molecule, and this is repeated for all four 
F As until optimal FA configuration i.s achieved (100). As previously stated, CL FA 
composition is species- and tissue-specific, and mammalian cardiac tissue predominantly 
expresses tetralinoleic CL, which is optimal for protein-CL binding (63). In mammalian 
neurons, however, over 100 different CL species exist, perhaps due to less dependence on 
aerobic respiration in neuronal cells relative to striated muscle (21 ). The FA composition 
of CL, and thus its remodelling mechanisms, are crucial determinants of whether CL will 
be able to bind to, and improve the activities of, the enzymes to which it is bound (11). 
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biosynthesis ., ... 
CL remodelling 
Figure 2. The cardiolipin (CL) metabolism pathway. 
MitoPLD 
MitoPLD, mitochondrial phospholipase D; PA, phosphatidic acid; CDS-112, CTP:PA 
cytidylyltransferase; CDP-DG, cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol; PGPS, 
phosphatidylglycerol-phosphate synthase; PGP, phosphatidylglycerol phosphate; PGPP, 
phosphatidylglycerol-phosphate phqsphatase; PG, phosphatidylglycerol; CLS, cardiolipin 
synthase; ALCAT-1, lysocardiolipin acyltransferase; MLCL, monolysocardiolipin; Taz, 
tafazzin; MLCL AT, monolysocardiolipin acetyltransferase 
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1.1.6.1 Fatty Acid Peroxidation 
The FA composition of CL tends to be unsaturated, which leaves its double bonds 
vulnerable to damage by ROS via peroxidation_ (88). CL is at an elevated risk of this 
damage due to its proximity to the ETC, a major producer of ROS (39). Is has been 
shown that mitochondrially-mediated production of ROS significantly decreases the 
enzymatic activities of complexes I, III and IV of the ETC via the peroxidation of CL 
(86-88). The peroxidation process becomes more likely, and more damaging, as the 
number of double bonds within the F As increase. Docosahexaenoic acid (DHA) is a ·22 
carbon loi;ig FA with six double bonds, and is a prime example of a highly peroxidation-
sensitive FA that binds to CL. Thus, numerous remodelling enzymes exist to ensure that 
-. 
the CL FA configuration allows optimal enzyme binding as well as maximal peroxidation 
resistance. Two examples are tafazzin (Taz) and acyl-CoA:lysocardiolipin 
acyltransferase-1 (ALCATl ). 
· 1.1.6.2 Tafazzin (Taz) 
Taz was first identified by an Italian group Bione et al. in 1996 (12). In light of 
their struggle to discover this protein, the group decided to name it after a masochistic, 
yet lovable, television character called Tafazzi. Taz is perhaps the most studied CL 
remodelling enzyme in humans, likely because its absence is known to cause Barth 
Syndrome, an x-linked human disease that is characterized by several myopathies (l; 9; 
12). At the molecular level, Taz is located in the intermembrane space and acts as a 
unique CL remodeler (13). Taz preferentially transfers linoleic FAs onto MLCL in a 
12 
CoA-independent manner. That is, it relies on other phospholipids (mainly PC) as FA 
donors/acceptors, which allow it to create the optimally functioning tetralinoleic CL (119). 
Taz-deficient neonatal ventricular myocytes have been shown to express decreased levels 
of CL, as well as lower ATP production ( 40). Taz KO mice have been generated and 
found to express increased levels of MLCL among a reduced CL pool, the remainder of 
which completely lacked tetralinoleic CL and had a higher degree of saturation (1; 51; 
106). In addition, these mice mimicked Barth Syndrome patients by exhibiting muscle 
weakness and cardiomyopathy (9; 106) 
1.1.6.3 Acyl-CoA:lysocardiolipin acyltransferase-1 (ALCATl) 
ALCATl is responsible for the acyl-CoA-dependent acetylation of MLCL and 
does not interact with other PLs such as lyso-PC, -PE or -PS (16). The expression of 
ALCATl is most abundant in heart and liver, where it is localized within the ER, MAMs, 
as well as the mitochondria (16; 69). This localization suggests that ALCATl acts on CL 
residing on the outer surface of the OMM. Unlike Taz, ALCATl lacks exclusivity to 
linoleic FA donor molecules (16). Alas, it is able to replace CL FAs with DHA, which is 
highly susceptible to peroxidation, and is found to be increasingly bound to CL in 
pathological conditions (69). DHA CL has been shown to significantly increase during 
pathological conditions such as heart failure in both humans and rats (96). 
Overexpression of ALCA Tl has been shown to increase the Jevels of DHA CL and 
reduce mitochondrial function, exhibited by increased ROS production, proton leakage 
and reduced mitochondrial DNA content and Complex I activity (69). The lack of 
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ALCATI has been shown to be beneficial for mitochondrial function, which was 
demonstrated by the use of ALCATI KO mice. These mice exhibited significantly more 
tetralinoleic-CL and -PG, CL's immediate biosynthetic precursor (58; 69). Accordingly, 
higher Complex I activity and reduced lipid _peroxidation were observed (69). These 
results, which point to ALCATI as a "bad" regulator of CL, are further corroborated by 
the ability of ALCATI to downregulate a monolysocardiolipin acyltransferase (MLCL 
AT), a "good" CL remodeler that adds only linoleic FA to MLCL (69; 110). ALCATI 
has also been found to be upregulated by ROS, a discovery that is helping elucidate the 
link between ROS production and mitochondrial dysfunction (69). 
I. I. 7 Current Research Trends in Cardiolipin 
Researchers have generated a Chinese Hamster Ovary cell line that has impaired 
PGP synthase activity, which leads to significantly decreased levels of CL. As a result of 
this intervention, mitochondrial swelling, cristae disruption, reduced ATP levels and 
lower oxygen consumption occurred (85). Complete CL ablation, however, has only been 
successful in organisms that can survive via anaerobic pathways, such as yeast. Yeast 
strains with a CLS (CrdI it?- yeast) null allele completely lack CL, while PGP synthase 
(PgsI in yeast) null allele cells lack both CL and PG. Crdt"-null yeast exhibited defective 
growth, impaired mitochondrial membrane potential as well as reduced ETC activity and 
protein import (19; 57; 111). The import of nuclear-encoded proteins into the 
mitochondria requires translocases of the IMM (TIM) and OMM {TOM) (I 02). The loss 
of mitochondrial import in CL-deficient cells has previously been attributed to. altered 
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membrane potential across the IMM. More recently, however, reduced assembly and 
function _of the TIM and TOM complexes have been observed under CL-deficient 
conditions, hinting that CL may directly influence the integrity of the mitochondrial 
protein import machinery (64; 109). The production of these cell lines has allowed 
researchers to explore the effects of CL deficiency, and continues to contribute to the 
growing body of knowledge on this unique phospholipid. 
1.2 Mitochondrial Biogenesis 
The plasticity of skeletal muscle is demonstrated by its ability to adapt to 
conditions of increased metabolic demand, such as exercise. One way that muscle adapts 
to such stimuli is through mitochondrial biogenesis, or the formation of new mitochondria. 
This process of organelle biosynthesis requires the coordination of nuclear, cytosolic and 
mitochondrial functions ( 47). There are multiple models used in laboratories that induce 
mitochondrial biogenesis, including treadmill running, overexpression of biogenesis-
inducing factors, the use of hormones such as thyroid hormone, as well as the activation 
of AMP-activated protein kinase (AMPK). It is important to note that there are two 
subpopulations of mitochondria, both of which adapt to exercise. These are the 
subsarcolemmal (SS) mitochondria, which are located underneath the muscle's 
sarcolemma, and the intermyofibrillar (IMF) mitochondria, which are nestled between the 
myofibrils (25). While 80% of the mitochondrial population is made up of the IMF 
subfraction, the SS population has been shown to adapt more readily to stimuli such as 
exercise and states of disease (27; 93). 
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1.2.1 Signalling pathways overview 
Contractile activity in skeletal muscle leads to mitochondrial biogenesis through a 
senes of molecular pathways. One major pathway involved in this process is 
implemented by intracellular calcium. During muscle contraction, calcium is released 
from the SR and leads to the increased expression of calcium.-induced genes, such as 
calcium/calmodulin-dependent protein kinases. Another signalling molecule that is 
activated by exercise is AMPK. Contractile activity in skeletal muscle reduces the ratio of 
ATP:ADP, and increases the levels of AMP, which allosterically activates AMPK (54). 
AMPK then translocates into the myonuclei and upregulates the gene expression of 
proteins involved in mitochondrial biogenesis (56). A third signalling molecule involved 
in this process is ROS, described below. 
1.2.1.1 ROS 
Mitochondria are the major producers of ROS in the cell, but ROS can also come 
from non-mitochondrial sources, such as the flavoprotein oxireductase system, located on 
the plasma membrane (89). Mitochondrially-produced ROS is generated when an electron 
is prematurely donated to an oxygen molecule at the ETC. In skeletal muscle, glycolytic 
muscle fibres have more ROS, relative to their oxidative counterparts and this, in part, is. 
due to the lower expression of ROS scavengers in glycolytic muscles (6). Within these 
different fibres types, the. SS mitochondrial subfraction has been shown to produce more 
ROS than the IMF fraction (3). Interestingly, ROS molecules were once considered to be 
solely detrimental, causing damage to mitochondrial DNA and resulting in the 
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peroxidation of phospholipids such as CL (30; 78). However, moderate levels of ROS, 
which are produced during exercise, have been shown to have adaptive effects (36; 92). 
This moderate level of ROS production increases mitochondrial DNA copy number, 
mitochondrial mass and produces elongation of the mitochondrial reticulum ( 46; 90). In 
an effort to elucidate the mechanisms behind these findings, ROS has also been shown to 
increase peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC-la) 
promoter activity as well as the expression of PGC-1 a and nuclear respiratory factor- I 
(NRF-1) (55; 107). 
1.2.2 Transcriptional Coactivator PGC-1 a 
PGC-1 a has often been called the master regulator of mitochondrial biogenesis. 
The protein expression of PGC-1 a was shown to increase with exercise training, as well 
as with acute exercise followed by recovery, while it decreased with muscle disuse (4; 8; 
54 ). At the molecular level, PGC-1 a is a transcriptional coactivator that binds to nuclear 
transcription factors and influences their interaction with DNA. 
1.2.2.1 PGC-1 a Overexpression 
Muscle-specific overexpression of PGC-1 a of an in vivo murine model exhibits 
increased mitochondrial content and improved endurance performance (15). The muscles 
of these mice also display a switch from glycolytic to more oxidative fibre types and are 
protected _against denervation-induced atrophy (97). This latter effect is likely due to the 
inhibitory action of PGC-la on Fox03, a protein involved in muscle atrophy (70; 97). 
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1.2.2.2 PGC-1 a Knockout Mice 
The generation of whole-body PGC-1 a knockout mice has helped elucidate the 
effects of this coactiv~tor in an intact physiological setting (71; 112). These mutant mice 
experience decreased endurance performance and reduced fatigue resistance (38; 68). A 
decrease in mitochondrial content and respiration was also observed, while the respiration 
deficit was able to be rescued with training ( 5). Some exercise physiologists might argue 
that one of the most intriguing characteristics discovered in the PGC-1 a knockout animals 
is their ability to adapt to exercise training (67; 112). It has been suggested that a 
compensatory mechanism performed by closely related coactivators, such as PGC-1 ~' 
may be at work tp induce this effect. 
1.3 Chronic Muscle Use 
Since the 1960s, it has been known that exercise is able to elicit mitochondrial 
adaptations in skeletal muscle ( 45). Each bout of contractile activity leads to the 
transcriptional activation of both nuclear- and mitochondrially-encoded genes ( 4 7). This 
exercise stimulus leads to the expansion of the mitochondrial network and to the 
alteration of mitochondrial composition ( 46). There are multiple rodent models used in 
research that simulate exercise, including treadmill and voluntary wheel running and 
chronic contractile activity (CCA). 
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1.3 .1 Endurance Exercise Training 
Endurance exercise with progressively increasing intensity has been found to 
result in mitochondrial biogenesis within 6-8 weeks of training (2; 47; 48). In rodent 
models, exercise can be administered via voluntary wheel running. This method allows 
animals to run at their own accord, which means that the exercise duration, frequency the 
running speed are all intrinsically determined. What is also under independent control is 
the time of day during which the exercise occurs. This is of particular importance due to 
the nocturnal activity patterns of rodents. Due to this intrinsic regulation, voluntary wheel 
running has been proven to elicit less of a stress response when compared to other 
approaches (31; 103 ). Two disadvantages of this method include the fact that it results in 
a lower exercise intensity, and it cannot control for variable exercise performances across 
animals. 
Another common method of exercise involves motorized treadmills, which are 
known to be of greater intensity when compared to wheel running. The treadmill exposes 
rodents to a forced running protocol in which the time of day, frequency, duration and 
progressively increasing intensity of exercise are all predetermined by the researcher ( 45). 
The use of air or electrical shocks is often administered to keep animals on track, which 
has been shown to further increase the stress response (83). A week-long conditioning 
period is usually used to help animals become accustomed to the treadmills, in an effort to 
reduce stress levels. Despite this effort, the use of treadmills elicits a greater stress 
response than the voluntary wheel running approach, one marker of which is increased 
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adrenal weight (83; 103). The advantage of this technique is that greater adaptations to 
exercise are observed than with the voluntary running wheel approaches. 
1.3 .2 Chronic Contractile Activity 
CCA is a method used to simulate the repeated contractions performed by skeletal 
muscle during endurance exercise. This protocol can be used with an animal model, as 
well as in cell culture (28; 108). In vivo, two electrodes are implanted on either side of a 
nerve, such as the common peroneal nerve, and electrical impulses are sent across the 
nerve, causing the innervated muscles to contract. In this case, the contracting muscles 
would be the tibialis anterior (TA) and the extensor digitorum longs (EDL). CCA is of 
particular benefit because it allows for a comparison to be made between an exercised and 
non-exercised muscle within the same animal, thus accounting for individual variability 
(108). Low-frequency stimulation has been shown to induce a training effect within just 
one week, thus it is also more time-efficient relative to treadmill and voluntary wheel 
running. CL content has also been shown to increase following just five days of CCA 
(108). A disadvantage of this protocol is the surgical invasiveness invol~ed with the 
implantation of the stimulator (108). Jn vitro, the same concept is applied in a cell culture 
model using skeletal muscle. cells (28; 112). A platinum wire electrode is placed on either 
side of the cell dish and is attached to a stimulator which causes the cells to contract (116). 
While this protocol induces similar increases in mitochondrial content compared to the in 
vivo model, it is somewhat disadvantageous because these isolated cells cannot 
experience the whole-body effects that a contracting muscle within an intact organism 
would (108; 112). 
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1.4 Chronic Muscle Disuse 
The effects of chronic muscle disuse are detrimental to the structure and function 
of skeletal muscle. The numerous models used in research that simulate muscle disuse 
include physical inactivity, bed rest, casting, exposure to microgravity, hindlimb 
suspension in rodents, as well as denervation and aging which are discussed in greater 
detail below. 
1.4.1 Denervation 
A denervation protocol involves the removal of a portion of a motor neuron, such 
as the common peroneal nerve, followed by subsequent analysis of the muscles it once 
innervated, again the TA and EDL in this case (117). Denervation is known to elicit a 
condition called sarcopenia, which is characterized by muscle fatigability and atrophy, or 
muscle fibre loss ( 4 ). This process occurs through an upregulation of apoptosis, an 
increase in protein degradation, and a decrease in the synthesis of newly formed proteins 
(91 ). Three days following common peroneal nerve denervation proved to be sufficient in 
reducing TA muscle mass, mitochondrial content, protein import and respiration levels in 
both SS and IMF subfractions ( 4; 104; 117). Following seven days of denervation, ROS 
production was significantly elevated, while CL levels were shown to decrease within 
five (104; 117). 
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1.4.2 Aging 
The skeletal muscle of aged mammals exhibits a decreased ability to develop 
force as well as a reduced muscle mass. Aged muscle is also more susceptible to the 
development of sarcopenia and has been shown to be less able to adapt to exercise-
induced changes, relative to their young counterparts (75). This decreased level of 
plasticity, however, has been debated. One group found that chronic, low-frequency CCA 
in rat skeletal muscle elicited the same mitochondrial adaptations in young and aged 
animals (105). On the other hand, different groups of research~rs have found that chronic 
exercise elicited increased muscle plasticity and fatigue resistance in young, but not aged 
skeletal muscle (75; 115). It was also found that the activation of exercise-induced 
kinases was attenuated in aged skeletal muscle and that endurance performance was 
significantly greater in the young, compared to the old (74; 75). These conflicting 
findings may be due to different protocol parameters, including rodent age, intensity of 
exercise and muscle fibres used for analyses (76). Regardless of these discrepancies, 
rodent models over the age of 26 months have consistently demonstrated attenuated 
exercise-induced muscle adaptations (74-77; 90; 115). This decreased adaptability of 
aged skeletal muscle suggests that a larger contractile stimulus is required to elicit the 
same adaptations (75; 76). 
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Abstract 
Cardiolipin (CL) is a phospholipid that maintains the integrity of mitochondrial 
membranes. We previously demonstrated that CL content increases with chronic muscle 
use, and decreases with denervation-induced disuse. To investigate the underlying 
mechffi1:isms, we measured the mRNA expression of 1) CL synthesis enzymes cardiolipin 
synthase (CLS) and CTP:PA-cytidylyltransferase-1 (CDS-1 ), 2) remodelling enzymes 
tafazzin (Taz) and acyl-CoA:lysocardiolipin acyltransferase-1 (ALCATl ), and 3) outer 
membrane CL enzymes, mitochondrial phospholipase D (MitoPLD) and phospholipid 
scramblase 3 (Plscr3), during chronic contractile activity (CCA)-induced mitochondrial 
biogenesis and denervation. With CCA, CDS-1 expression increased by 128%, 
parelleling CL levels. Surprisingly, denervation also led to large increases in CDS-1 and 
CLS, despite a decrease in mitochondria, possibly due to a compensatory mechanism to 
restore lost CL. ALCATl decreased by 32% with CCA, but increased by 290% following 
denervation, indicating that both CCA and denervation alter CL remodelling. CCA and 
denervation also elicited 60-90% increases in Plscr3, likely to facilitate CL movement to 
the outer membrane. The expression of these genes was not affected by aging, but 
changes due to CCA and denervation were attenuated compared to young animals. The 
absence of PGC-1 a in knockout animals led to a decrease in CDS-1 and an increase in 
ALCATl mRNA levels, implicating PGC-1 a in regulating both CL synthesis and 
remodelling. These data suggest that chronic muscle use and disuse modify the 
expression of mRNAs encoding CL metabolism enzymes. Our data also illustrate, for the 
first time, that PGC-1 a regulates the CL metabolism pathway in muscle. 
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Introduction 
The membranes of mitochondria have a diverse structure consisting of many 
molecules including cholesterol, proteins and phospholipids. The most abundant 
structures are the phospholipids, which further contribute to the diversity of membranes 
through their varied forms. Cardiolipin (CL) is a phospholipid exclusive to the 
mitochondria, with 90% of it localizing in the inner mitochondrial membrane (IMM), 
with the remaining 10% on the outer mitochondrial membrane (OMM) (13). CL exists as 
a dimer and .is composed of four fatty acid (FA) chains which must be dynamically 
transferred and remodelled to ensure proper membrane configuration (18). The majority 
of these FA molecules are unsaturated, making them highly susceptible to peroxidation 
via reactive oxygen species (ROS). CL also binds to components of the electron transport 
chain (ETC), a major producer of ROS, and is therefore at even greater risk of 
peroxidation (19). When CL is peroxidized, proton leak is increased across the IMM, thus 
inhibiting energy production and leading to pathology (14). 
A complex molecular pathway is involved in synthesizing and ensuring proper CL 
structure. Cardiolipin synthase (CLS) is a key enzyme involved in the de novo 
biosynthesis of immature CL, which occurs on the inner leaflet of the IMM (6). Another 
crucial enzyme involved in this pathway is CTP:PA cytidylyltransferase (CDS-I), the rate 
;-" 
limiting step of this biosynthesis process (13). In order to function optimally, immature 
CL must have its F As remodelled into a mature form. Two key enzymes involved in this 
are tafazzin (Ta2) and acyl-CoA:lysocardiolipin acyltransferase-1 (ALCATl ). Taz 
remodels the FAs of CL to create a mature CL molecule (4), while ALCATI converts the 
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FAs back to the immature form (14). CL can also be transferred between the IMM and 
OMM by the membrane-embedded enzyme phospholipid scramblase-3 (Plscr3) (21 ). This 
is critical, as the location of CL has been found to influence its cellular role (12). IMM 
CL that is bound to the ETC complexes helps to stabilize and align them to ensure proper 
electron transfer (7), while CL that is located on the OMM aids in the assembly of import 
_machinery, and acts as a binding site for tBid, which triggers apoptosis (11; 12). OMM 
Ct is also at risk of being cleaved and converted to phosphatidic acid (PA) by 
mitochondrial phospholipase D (MitoPLD), which acts only on adjacent mitochondria 
(8). MitoPLD, therefore, is of particular importance, as it has the ability to mediate the 
amount of CL that resides on the OMM. 
The synthesis and remodelling of CL is crucial for the integrity of the 
mitochondrial membrane and overall functioning of the organelle. We have previously 
shown that chronic contractile activity (CCA), a_ form of muscle use, elicits a significant 
increase in CL content (20). In contrast, denervation, a form of muscle disuse, 
significantly decreases CL concentration within muscle (22). The mechanisms underlying 
these changes have yet to be examined. Thus, the purpose of this study is to examine the 
adaptations of the enzymes of the CL metabolism pathway during changes in 
mitochondrial biogenesis. We set out to analyze the expression of the six aforementioned 
enzymes in response to conditions of chronic muscle use and disuse, and the effect of 
aging. Further, since many mitochondrial proteins are regulated by the transcriptional 
coactivator PGC-1 a, we also evaluated the role of this protein in the regulation of CL 
metabolism enzymes. We hypothesized that the gene expressions of the enzymes 
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involved in CL biosynthesis and remodelling would increase with CCA and decrease with 
denervation and PCG-1 a knockout conditions. We also predicted that the expression of 
enzymes that reduce CL content or function would be downregulated with CCA and 
increased with denervation and PCG-1 a knockdown. The combined effects of these 
changes would result in increased CL content with CCA, and decreased content in 
denervated and PCG-1 a knockout rodents. This could contribute to the expansion and 
degradation of mitochondrial membranes as alterations in mitochondrial content occur. 
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Methods 
Animals. Male Sprague-Dawley (SD; Charles River, St. Constant, QC, Canada) 
rats were purchased at six-months of age. Male Fischer 344 X Brown Norway 
(F344XBN; National Institute on Aging, Bethesda, MD, USA) Fl hybrid rats were 
divided into one of two groups depending on age: six-months (young) or 33-months old 
(aged). One set of young and aged rats were designated for our CCA protocol (n=lO for 
both young and, aged), while a separate set was used for denervation (n=8 for both young 
and aged). The generation of PGC-1 a knockout mice used were as was previously 
described (15), and are bred in our facility. Offspring were genotyped by crude DNA 
extraction from ear clippi:rigs. DNA was combined with DNA Taq polymerase (Jumpstart 
REDtaq Ready Mix PCR Reaction Mix, Sigma, Oakville, ON, Canada) and primers 
specific for wildtype or knockout genes, and were detected using traditional PCR 
methods. Mice were used at 10 months of age. All animals were housed individually 
under a 12-12h light-dark cycle in a temperature controlled room (20-21°C) and were 
given food and water ad libitum. Animal usage in this study followed protocols that were 
approved by the York University Animal Care Committee, in accordance with the , 
Canadian Council on Animal Care. 
In vivo stimulation protocol. Portable stimulation devices were unilaterally 
implanted into the animals as previously described (20). In brief, rats were anesthetized 
with a ketamine-xylazine cocktail (0.2 mL/100 g body weight). Electrodes (Medwire, 
Leico Industries, New York, NY, USA) located unilaterally at either side of the common 
peroneal nerve caused palpable contractions in the tibialis anterior (TA) and extensor 
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digitorum longus (EDL) muscles. All implantations were followed by a week-long 
recovery period, upon which stimulation began. The CCA protocol lasted for 3 hours a 
day, for 7 days, with 21 hour recovery periods in between. The stimulation frequency was 
10 Hz. Stimulation units were externalized for the SD rats (20), while the F344XBN rats 
had silicone-encased stimulators inserted into the intraperitoneal cavity, and sutured to the 
musculature of the abdomen (16). All other surgical procedures and stimulation protocols 
were identical between the two rat strains. The rats were then anesthetized and the 
stimulated TA and EDL muscles were removed. The non-stimulated, contralateral 
muscles served as internal controls. Upon_ removal, half of the TA muscles were used 
immediately for mitochondrial isolation. The remaining half of the TA, as well as the 
EDL muscles, were frozen in liquid nitrogen and pulverized into a fine powder for 
subsequent experiments. The animals were sacrificed by removal of the heart. 
· In vivo denervation protocol. Male, 6-month old, SD rats underwent unilateral 
common peroneal denervation as previously described (10). Briefly, rats were 
' 
anesthetized with a ketamine-xylazine mix (0.2 ml/100 g body weight). The common 
pert:meal nerve was exposed ·and a 0.5 cm long segment was removed. Following 7 days, 
both EDL muscles were removed and the non-denervated, contralateral muscles were 
used as internal controls. The tissues were then frozen in liquid nitrogen, and then 
pulverized into a fine powder. 
Cytochrome c oxidase (COX) activity. COX activity was used as a marker of 
mitochondrial biogenesis. Pulverized whole muscle homogenates were prepared and 
sonicated for 10 son ice at a power output of 20-30%. A buffered test solution was also 
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prepared, containing fully reduced horse heart cytochrome c (C-2506, Sigma, Oakville, 
ON, Canada). Using a multipipette, 250 µL oftest solution were added to 20 µL of whole 
muscle homogenate in a 96-well plate. The enzyme activities of the homogenates were 
analyzed by measuring the maximal oxidation rate of cytochrome c. This was done via 
the absorbance change at 550 nm at 30 °C in a Synergy HT (Bio-tek Instruments, 
Winooski, VT, USA) microplate reader. For each sample, the COX activity measurement 
was calculated as an average of three trials. 
In vitro RNA isolation and reverse transcription. Total RNA was isolated from 
frozen, whole muscle EDL powders. Tissue powder (·.,90 mg) was added to 1 mL of 
TRlzol® Reagent (lnvitrogen, Carlsbad, CA, USA) and homogenized for 30 s at a power 
output of 30%. Upon 5 min of incubation at room temperature, 200 µL of chloroform was 
added and tissues were shaken for 15 s. Following another 3 min of room temperature 
incubation, samples were centrifuged at 4°C at 16 000 g for 15 min. Next, the upper 
aqueous phase of the sample was transferred into a new tube along with 500 µL of 
isopropanol, shaken for 15 sand left overnight at -20°C to precipitate. Samples were then 
centrifuged at 4 °C at 16 000 g for 10 min. The resultant supernatant was discarded, and 
the pe.llet was washed with 700 µL of 75% ethanol. Following a centrifugation (10 min, 
4 °C), the supernatant was discarded and the pellet was resuspended in 100 µL of sterile 
water. The concentration and purity of the RNA were measured at 260 nm and 280 nm, 
respectively (Ultrospec 2100 Pro, Biochrom, Cambridge, UK). The quality of the RNA 
was determined by observing the 28S and 18S bands on a 1 % formaldehyde-agarose gel. 
Following the manufacturer's recommendations, SuperScript® III reverse transcriptase 
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(Invitrogen, Carlsbad, CA, USA) was used to reverse transcribe 1.5 µg of total RNA into 
cDNA. 
Real-time PCR. Using sequences from GenBank, primers were designed with 
Primer 3 v. 0.4.0 software (Massachusetts Institute of Technology, Cambridge, MA, USA) 
for genes of interest: CDS-1, CLS, Taz, ALCATl, MitoPLD and PlscrJ (Tables 1-2). 
Primer specificity was confirmed by OligoAnalyzer 3.1 (Integrated DNA Technologies, 
Toronto, ON, Canada). mRNA expression was measured with SYBR® Green chemistry 
(PerfeCTa SYBR® Green SuperMix, ROX, Quanta BioSciences, Gaithersburg, MD, 
USA). Each well contained: SYBR® Green SuperMix, forward and reverse primers (20 
µM), sterile water and 10 ng of cDNA. In cases where functioning primers could not be 
designed, 1.25 µL of TaqMan probes was used along with 12.5 µL TaqMan Universal 
Master Mix (4304437, Life Technologies, Carlsbad, CA, USA; Table 1) with 10 ng of 
cDNA and 7 .25 µL of water per well. The detection of all real-time PCR amplification 
took place in a 96-well plate using a StepOnePlus® Real-Time PCR System (Applied 
Biosystems Inc., Foster City, CA, USA). The final reaction volume of each well was 25 
µL. Samples were run in duplicates to ensure accuracy. The PCR program consisted of an 
initial holding stage (95°C for 10 min), followed by 40 amplification cycles (60°C for 1 
min, 95°C for 15 s ), and was completed with a final melting stage (95°C for 15 s, 60°C 
for 1 min, 95°C for 15 s). Nonspecific amplification and primer dimers were controlled 
for by the analysis of melt curves generated by the instrument for SYBR® Green analyses. 
Negative control wells contained water in place of cDNA. 
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Real-time PCR quantification. First, the threshold cycle (CT) number of the 
endogenous reference gene was subtracted from the CT number of the target gene 
(~CT=CT(target)-CT(reference)). Next, the ~CT value of the control tissue was subtracted from 
the ~CT value of the experimental tissue (~~CT=~CT{experimental)-~CT(control)). Results 
were reported as fold-changes using the ~~CT method, calculated as 2-McT_ Different 
endogenous control genes were tested and selected based on the highest p-value 
computed in a t-test comparing control· and experimental muscles. The CT values of 
selected control genes were averaged using RT2 Profiler PCR Array Data Analysis 
software(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php, SABiosciences, 
QIAGEN Inc., Toronto, ON, Canada). For CCA, myelocytomatosis oncogene (Myc) and 
ribosomal protein Rps12 were chosen, whiltr primers detecting glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) and P-Actin were used as·endogenous controls for the 
denervated samples. Rps 12 was used as an endogenous control for the aged CCA 
samples, while Rps12 and P-Actin were averag~d for aged denervated samples. For PGC-
1 a mouse tissues, P2-microglobulin, P-Actin and Gapdh were averaged (Table 2). 
Subsarcolemmal (SS) mitochondria isolation. TA muscles were excised and 
tissues were immediately submerged in I 0-20 mL of buffer. The TA muscles were then 
patted dry, cut away from any excess connective tissue or fat, minced and homogenized. 
The mitochondrial SS isolation procedure has been previously described (9). The 
mitochondria were suspended in resuspension medium and were then used in flow 
cytometry. The amount of mitochondrial protein was determined using the Bradford 
protein assay. 
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Mitochondrial cardiolipin content. Flow cytometry was used to measure CL 
content in isolated SS mitochondria using a four-Golour F ACSCalibur flow cytometer 
equipped with a 488 nm argon laser (Becton Dickinson, San Jose, CA, USA). 
Mitochondrial CL content was measured using the fluorescent probe 10-N-Nonyl-3,6-
bis(dimethylamino) acridine orange (NAO) as previously described (5). Measurements 
were made on taken from 50 µg of SS mitochondria isolated from rat or mouse TA 
muscles. Data were collected from the forward-scatter and side:.scatter light detectors. 
The flow cytometry data were obtained following a minimum of 20 000 gated events. 
Statistical Analyses. To compare between control vs. stimulated and control vs. 
denervated muscles, paired t-tests were performed, while wildtype vs. knockout muscles 
were compared using unpaired t-tests. A split-plot ANOV A calculation was used to 
analyze results from the CCA and denervated tissues within the aging muscles, followed 
by a Bonferroni post hoc test. To analyze the relative expression of the different 
transcripts, a one-way ANOV A was performed with a Bonferroni post hoc test. All 
statistical analyses were performed using GraphPad Prism 4.0 software. The critical p-
value was set atp<0.05. All error bars represent the standard error of the mean. 
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Table 1. List of enzyme names, abbreviations and functions. 
Enzyme Name Abbreviation Function 
CTP:P A cytidylyltransferase CDS-1 Rate-limiting step of CL de novo biosynthesis 
Cardiolipin synthase CLS Final enzyme in CL de novo ~iosynthesis 
Tafazzin Taz Remodels CL fatty acid to m~ture form 
Acyl-CoA:lysocardiol~pin ALCATI Remodels CL fatty acid to immature form 
acyltransferase-1 
Mitochondrial phospholipase D MitoPLD Cleaves CL present on outer membrane to 
phosphatidic acid 
Phospholipid scramblase-3 Plscr3 Transfers CL to the outer membrane 
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Table 2. List of primer sequences and probes used in qPCR analyses. Alternative names 
use d. h' . . th m t is paper are wntten m paren eses. 
Gene, Type Accession Forward Primer Reverse Primer 
Size (bp) Number 
CDS-1 Rat NM_ Applied Biosystems TaqMan Probe Assay JD Rn00579942_ml 
031242.2 
Lclatl Rat XM_ Applied Biosystems TaqMan Probe Assay ID Rn01468447 _ml 
(ALCATI) 343020.4 
Rpsl2 Rat NM_ Applied Biosystems TaqMan Probe Assay ID Rn01789993_ul 
031709.3 
Myc Rat NM_ Applied Biosystems Ta~Man Probe Assay ID Rp0056~507_ml 
012603.2 
Gapdh Rat NM_ Applied Biosystems TaqMan Probe Assay JD RnOJ 775763_gl 
017008.13 
P-Actin Rat NM_ Applied Biosystems TaqMan Probe Assay JD Rn00667869 _ml 
031144.2 
Crist Rat NM_ 5'-AAT GIT GAT CGC TGC TGT GIT T-3' 5'-ITA GCT AGT GIT CGC GGT GTT G-3' 
(CLS), 66 00!014258.1 
Taz, Rat NM_ 5'-CGG CTG AIT GCT GAG TGT CA-3' 5'-TCA ITCAITCCAACA TGCCAT AG-3' 
63 00!025748.l 
Pld6 Rat XM_ 5'-TCA TCA CGG ACT GCG ACT A-3' 5'-GGC AAA CTT ATG GTG CAT GT-3' 
(MitoPLD) 220517.3 
116 
Plscr3, Rat NM_ 5'-GCA CCA AAG ATG GCA GAT A-3' 5'-TAA TAG CTG TAG GGT TGG GAC C-3' 
120 00!012139.2 
Myc, Rat NM 5'-GCT CTG CTC TCC GTC CTA TGT-3' 5'-ATG ACC GAG CTA CIT GGA GG-3' 
123 0126o3.2 
Rps12, Rat NM_ 5'-ATG GAC GTC AAC ACT GCT CT-3' 5'-ATC TCTGCG TGC ITG CAT-3' 
127 031709.3 
Gapdh, Rat NM_ 5'-CTC TCT GCT CCT CCC TGT TCT A-3' 5'-GGT AAC CAGGCG TCC GAT AC-3' 
122 017008.3 
P-Actin, Rat NM_ 5' -CCC CAT TGA ACA CGG CAT T-3' 5'-GCC AAC CGT GAA AAG ATG ACC-3' 
154 031144.2 
CDS-I Mouse NM_ Applied Biosystems TaqMan Probe Assay ID Mm01208328_ml 
173370.3 
B2M Mouse NM_ Applied Biosystems TaqMan Probe Assay ID Mm00437762_ml 
009735.3 
P-Actin Mouse NM_ Applied Biosystems TaqMan Probe Assay ID Mm00607939 _sl 
007393.3 
Gapdh Mouse NM_ Applied Biosystems TaqMan Probe Assay ID Mm99999915_gl 
008084.2 
Crist, Mouse NM_ 5'-GGT GIT GCACAGCAITCA-3' 5'-GCT GGA TCT GGG TGC ITC T-3' 
I07 00!024385.1 
Taz, Mouse NM_ 5'-CCC TCC ATG TGA AGT GGC CAT TCC-3' 5' -TGG TGG TTG GAG ACG GTG AT A AGG-3' 
205 001173547.l 
Lclatl Mouse NM 5'-AGC TGT ITG ACT CCC TAG T-3' 5'-TGA rec A TC AGA GAA ACT TA-3' 
(ALCATI) 00108 !07 l.2 
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Pld6, Mouse NM_ 5'-CAC AAG TIT GCC ATC GIT GA-3' 5'-GGA ACA GCC GCA CAT ACT-3' 
(MitoPLD) 183139.2 
127 
Plscr3, Mouse NM_ 5'-CTG ATC GCC AAC CTG TTC TA-3' 5'-CTT CGC GAT TCA TCC TIA GT-3' 
IOO 023564.4 
B2M, Mouse NM_ 5'-GGT CIT TCT GGT GCT TGT CT-3' 5'-TAT GIT CGG CIT CCC ATT CT-3" 
106 009735.3 
P-Actin, Mouse NM_ 5'-TGT GAC GTT GAC ATC CG TAA-3" 5'- GCT AGG AGC CAG AGC AGT AA-3" 
117 007393.3 
Gapdh, Mouse NM_ 5' -AAC ACT GAG CAT ere CCT CA-3" 5'-GTG GGT GCA GCG AAC TIT AT-3" 
113 008084.2 
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Results 
Chronic muscle use. We elicited the effects of chronic muscle use by employing 
the chronic contractile activity (CCA) model. COX activity was used as a marker of 
mitochondrial content. CCA resulted in a 40% increase (p<0.05) in COX activity per 
gram of muscle compared to the contralateral.control muscles (Fig.IA). Previous work in 
our laboratory has shown that seven days of CCA increases CL content by 48% (20), 
reflecting changes in mitochondrial content, since the levels closely paralleled COX 
activity, as well as possible changes in organelle composi~ion. We also measured the 
mRNA expression of CDS-1, CLS, Taz, ALCATl, MitoPLD and Plscr3. With CCA, the 
mRNA levels of CDS-1 and Plscr3 increased significantly by 128% and 90%, 
respectively. In contrast, CCA led to decreases in ALCATl and MitoPLD mRNA levels 
of 32% and 40%, respectively (p<0.05; Fig. 1 C). 
Chronic muscle disuse. To contrast with chronic muscle use, we employed 
denervation, a.model of muscle disuse. Seven days of denervation lead to a significant 
33% decrease in COX activity (p<0.05; Fig. 2A). Previous work has shown that a similar 
period of denervation decreases CL content by 40% (22), thus matching the observed 
. change in COX activity. Following denervation, the mRNA expression of CDS-1, CLS, 
ALCATl and Plscr3 all increased by 280%, 58%, 290% and 59%, respectively (p<0.05; 
Fig. 2B), while the expression ofTaz and MitoPLD remained unaltered. 
Chronic muscle use and aging. In aged animals, muscle COX activity was 
diminished by 15-20%. CCA resulted in a 50% increase in COX activity in young 
animals, but only in a 40% augmentation in the aged animals (p<0.05; Fig.3A). 
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Mitochondrial CL content was increased by 26% with CCA (p<O.OS), but only in young 
animals as this response was eliminated with age (Fig.3B). This reflects a change in 
organelle composition with CCA, since CL was measured in the mitochondrial fraction. 
With respect to CL metabolism enzymes, CDS- I expression increased significantly by 
240% in young, and by 88% in aged animals following CCA, while CLS remained 
unaltered (p<0.05; Fig.3C-D). With respect to the CL remodelling enzymes, Taz mRNA 
levels were not altered by CCA, or aging. The mRNA levels of ALCATI and MitoPLD 
both decreased by 30% as a result of CCA in young animals, while Plscr3 increased by 
178%. These three effects were all attenuated with age (p<O.OS; Figs.4B-D). 
Chronic muscle disuse and aging. A separate set of aged animals was used to 
investigate the combined effect of aging and chronic muscle disuse produced by 
denervation. In these animals, a 30% difference in COX activity was observed between 
muscles of young and old animals. Denervation resulted in a 50% and 34% decrease in 
mitochondrial content in both the young and aged muscles, respectively (p<O.OS; Fig.SA). · 
CDS-1 mRNA expression increased by 100% following denervation in young animals 
only (p<0.05; Fig.SB), while CLS increased by 56% and 38% in the young and aged 
animals, respectively (p<O.OS; Fig.SC). When we measured CL remodelling enzyme 
expression, there was no effect of denervation or agi~g on Taz (Fig.6A) or MitoPLD 
(Fig.6C) mRNA levels. ALCATI, however, increased with denervation by 208%. While 
ALCATI did not change with aging in control muscle, it decreased by 67% in aged, 
denervated muscle (Fig.6B). For Plscr3, we observed 33% and 20% increases following 
denervation in young and aged animals, respectively (p<0.05; Fig.6D). 
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PGC-la knockout conditions. To investigate a role for the transcriptional 
. coactivator PGC-1 a in the regulation of CL metabolism, we used PGC-1 a knockout 
animals. Muscle from the ariimals exhibited a 42% decrease in COX activity relative to 
wildtype animals, reflecting a decline in organelle content per gram of muscle. CL 
content in the SS mitochondrial fraction remained unaltered (p<0.05; Figs.7A-B). The 
lack of PGC-1 a resulted in a significant decrease in CDS-1 ( 61 % ) while ALCA T 1 
significantly increased by 97% (p<0.05; Fig.7C). 
Relative gene ex.pression levels in rats and mice. We also sought to use a 
comparative approach to analyze the relative mRNA expression levels of CL metabolism 
enzymes in rat and mouse muscle. Of the CL de novo biosynthesis enzymes, CDS-1 had 
the lowest level of expression in both the rat and mouse. This is consistent with CDS-1 as 
the rate-limiting enzyme in the CL synthesis pathway. Of the remodelling enzymes, the 
expression of Taz and ALCATl was similar in the rat, however, Taz was significantly 
higher than ALCATl in mouse. When we compared the expression levels of the OMM 
enzymes MitoPLD and Plscr3, we found Plscr3 to be significantly higher th~ MitoPLD 
in both species (Fig.8A-B; p<0.05). 
53 
Discussion 
The objective of this study was to investigate the underlying basis for previously 
discovered findings that CL concentration increases with muscle use, and decreases with 
muscle disuse. To do this, we used similar conditions of muscle use and disuse as 
previously reported, and measured COX activity to confirm that we were successful at 
altering mitochondrial content. We next set out to compare the CL content in muscle 
under these conditions, with the expression of the enzymes involved in the CL 
metabolism pathway. We chose to examine the mRNA levels of these enzymes I) due to 
the lack of suitable antibodies and 2) to provide a comprehensive analysis of the trends in 
gene expression within the pathway as produced by stimuli which alter mitochondrial 
biogenesis. 
We analyzed enzymes of the CL de novo biosynthesis, remodelling and outer 
mitochondrial membrane pathways following CCA, denervation, and another from of 
muscle disuse, aging. Our . expectation was that the expression of the biosynthesis 
enzymes CDS-I and CLS would increase with CCA and decrease with denervation, thus 
paralleling mitochondrial and CL content. We found that CCA induced an increase in 
CDS-I, while CLS remained unaltered. Thus, the increase in CL content measured with 
muscle use is accompanied by the up-regulation of certain, but not all CL biosynthesis 
genes. Since CDS-I is the rate-limiting enzyme in CL biosynthesis (13), the augmented 
expression_ of CDS-I correlates well with the increase of CL in CCA-treated muscle~ Our 
comparative approach to analyze the relative mRNA levels of these enzymes confirmed 
the probable rate-limiting function of CDS-I, since CDS- I mRNA ·levels were among the 
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lowest of the genes measured in both rat and mouse muscle. However, we were surprised 
to find that denervation also elicited increases in the mRNAs encoding these biosynthesis 
enzymes. Our observations are suggestive of a secondary, compensatory response which 
occurs during chronic muscle disuse to restore the lost organelle CL content during this 
condition (22). 
Taz and ALCATI are enzymes responsible for the remodelling of CL F As. Taz 
has been shown to transfer linoleic F As onto CL, thus creating mature, functional 
tetralinoleic CL. A loss of function mutation in the Taz gene in humans has been shown 
to lead to Barth syndrome, which is characterized by numerous myopathies (3). Iri 
contrast, ALCATI has been shown to add polyunsaturated FAs onto CL, creating an 
immature form of the molecule which is elevated during pathological conditions (14). 
Based on this, we hypothesized that Taz and ALCATI expression would change in 
opposite directions with chronic muscle use, and also with muscle disuse conditions. 
Surprisingly, Taz was completely unresponsive to the treatments. However, ALCATI 
decreased with CCA, and became elevated following denervation. This suggests that 
chronic muscle use not· only elevates CL levels, but also serves to induce a more 
functional form of the phospholipid. Interestingly, the higher level of Taz relative to 
ALCATI in the mouse, compared to the rat, suggests that CL in mouse muscle may have 
a greater ratio of functional to nonfunctional CL than in rat muscle. 
MitoPLD and Plscr3 both interact with CL on the outer mitochondrial membrane. 
Plscr3 serves to transport CL from the inner to the outer mitochondrial membrane, 
thereby dispersing CL within the organelle. MitoPLD, on the other hand, cleaves outer 
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membrane CL into PA, thereby reducing total CL content. We hypothesized that CCA 
would induce Plscr3 to help redistribute the increase in CL content, while MitoPLD 
would decline to facilitate this process. We found that CCA elicited this response in both 
of these enzymes, supporting our hypothesis. To our surprise, denervation elicited a 
similar effect. We speculate that this alteration may serve a very different purpose during 
chronic mu~cle disuse. The increase in outer mitochondrial membrane CL may act as a 
binding site for tBid, which triggers cytochrome c release and leads to mitochondrially-
mediated apoptosis. Thus, the effect may be a contributing factor to the previously 
reported increased apoptotic susceptibility following denervation (1 ) .. Our comparative 
analyses of mRNA levels showed the existence of high ratios of Plscr3 relative to 
MitoPLD in both mouse and rat. This suggests that the need for CL transport to the outer 
membrane is greater than that for CL cleavage under steady state conditions. 
When we analyzed the CL levels within mitochondria of young and aged animals, 
we found no difference between the two age groups. This finding was in parallel with the 
lack of difference exhibited for the measured mRNAs~ In general, the response of aging 
animals to either CCA or denervation was attenuated compared to the responses observed 
in young animals. Notably, both the protective CCA-, and the detrimental denervation-
induced changes of ALCATl were lost with age. CCA-induced changes of MitoPLD and 
Plscr3 were also both reduced with aging. These findings are consistent with the 
observation that aging muscle can adapt to variations in chronic muscle use or disuse, but 
that the response is attenuated compared to that in young muscle ( 17). 
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In an effort to elucidate the transcriptional underpinnings behind our observations, 
we examined the possible role of PGC-1 a. PGC-1 a is an established nuclear coactivator, 
often referred to as the master regulator of mitochondrial biogenesis because its activation 
or overexpression promotes the transcription of a wide variety of nuclear gene products 
that are destined for the mitochondria. However, its function is currently unknown 
regarding its regulation of the transcripts of genes encoding enzymes of CL. PGC-1 a has 
been shown to be elevated by CCA (2), while chronic muscle disuse via denervation 
downregulates PGC-la levels (1). Thus, we used PGC-la knockout animals to determine 
whether this transcriptional coactivator is involved in mediating the mRNA changes 
observed. We found that CDS-1 was suppressed by the absence of PGC-1 a, suggesting 
that the coactivator directly regulates CL expression of this rate-limiting enzyme, and 
therefore the flux through the CL biosynthesis pathway. Indeed, inspection of the CDS-1 
promoter reveals binding sites for MyoD, USF-1, NF-kappa B, PPAR-gamma, CREB and 
MEF-2, all transcription factors through which PGC-1 a may be acting. Considerable 
further work is required to verify the possible functional nature of these binding sites 
within the CDS-1 promoter region. With respect to the remodelling enzymes, ALCATl 
levels were increased in the absence of PGC-la. This suggests that PGC-la normally 
suppresses ALCATl, thereby exhibiting a protective role on the fatty acid composition of 
CL. In contrast, neither of the outer membrane CL remodelling genes was affected by the 
absence of PGC-1 a. Thus, PGC-1 a has a selective role in regulating the transcription of 
CL metabolism enzymes. 
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This study provides the first detailed analysis of the expression of CL synthesis 
and remodelling enzymes in skeletal muscle. Our results set the stage for further 
exploration of this complex network of mitochondrial membrane regulators, particularly 
when suitable antibodies become available. Both protein level measurements, as well as 
the localization of these enzymes will be crucial for the expansion of our knowledge 
regarding this molecular pathway. All CL biosynthetic enzymes are nuclear-encoded 
proteins. Thus, they rely on the mitochondrial import machinery in order to ~e transported 
into the mitochondria to manufacture or modify CL. It would therefore be of great 
interest to analyze the trafficking, localization and possible post-translational 
modifications of many of these enzymes following chronic muscle use or disuse, or in 
diseases of phospholipid metabolism. Our data suggest that the transcriptional activation 
of certain genes responsible for CL synthesis is upregulated during muscle use, perhaps to 
produce more CL, and also during muscle disuse as part of a possible compensatory 
mechanism. Many of these observed effects are lost with aging. Finally, it was notable 
that some CL metabolism genes are regulated by PGC-1 a, documenting a role for this 
coactivator in mitochondrial phospholipid synthesis, alongs~de its well established 
function in the regulation of typical nuclear genes encoding mitochondrial proteins. 
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Figure Legend 
Figure 1. Effects of CCA on mitochondrial content, CL levels and mRNA expression in 
skeletal muscle. (A) Average COX activity in CCA and control muscles (n=8); (B) Tissue 
CL content in control and 7-day CCA muscles (data from Takahashi & Hood, 1993; 
n=7); (C) mRNA levels of CDS-I, CLS, Taz, ALCATI, MitoPLD and Plscr3 in 
chronically stimulated muscles (n=8). Graph represents fold-changes relative to control 
muscles. Values are representative of means+/-SEM; p<0.05; *vs. control. 
Figure 2. Effects of denervation on mitochondrial content, CL levels and mRNA 
expression in skeletal muscle. (A) Average COX activity in denervated and control 
muscles (n=8); (B) Tissue CL content in control and 8-day denervated muscles (data from 
Wicks & Hood, 1991; n=7); (C) mRNA levels ofCDS-1, CLS, Taz, ALCATl, MitoPLD 
and Plscr3 in denervated muscles (n=8). Graph represents fold-changes relative to ~ontrol 
muscles. Values are representative of means+/..:.SEM; p<0.05; *vs. control. 
Figure 3. Effects of CCA and age on mitochondrial content, mitochondrial CL levels and 
mRNA expression in skeletal muscle. (A) Average COX activity in young and aged, 
control and CCA muscles (n=lO); (B) CL content of isolated SS mitochondria from 
young and aged, control and CCA muscles (n=9). mRNA levels of cardiolipin de novo 
biosynthesis enzymes (C) CDS-l; and (D) CLS in control and stimulated muscles of 6-
month and 36-month old rats (n=6 for each group). Empty bars represent control muscles, 
filled bars represent CCA muscles. Values are representative of means+/-SEM; p<0.05; * 
vs. control; ** main effect of aging. 
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Figure 4. mRNA levels of cardiolipin remodelling and outer membrane enzymes. (A) Taz; 
(B) ALCATl; (C) MitoPLD; and (D) Plscr3 in control and stimulated muscles of 6-
month and 36-month old rats. Empty bars represent control muscles, filled bars represent 
CCA muscles. Values are representative of means+/-SEM; n=6 for each group; p<0.05; * 
vs. control; ** main effect of aging. 
Figure 5. Effects of denervation and age on mitochondrial content and mRNA expression 
in skeletal muscle. (A) Average COX activity in young and aged, control and denervated 
muscles (n=8). mRNA levels of cardiolipin de novo biosynthesis enzymes (B) CDS-1; 
and (C) CLS in control and denervated muscles of 6-month and 36-month old rats (n=6 
for each group). Empty bars represent control muscles, filled bars represent denervated 
muscles. Values are representative of means+/-SEM; p<0.05; *vs. control;** main effect 
of aging. 
Figure 6. mRNA levels of cardiolipin remodelling and outer membrane enzymes. (A) Taz; 
(B) ALCATl; (C) MitoPLD; and (D) Plscr3 in control and denervated 6-month and 36-
month old rats. Empty bars represent control muscles, filled bars represent denervated 
muscles. Values are representative of means+/-SEM; n=6 for each group; p<0.05; * vs. 
control;** main effect of aging. 
Figure 7. Effects of PGC-la knockOut on mitochondrial content, mitochondrial CL levels 
and mRNA expression in skeletal muscle. (A) Average COX activity of PGC-1 a knockout 
and wildtype mice (n=4); (B) CL content in isolated SS mitochondria of wildtype and 
PGC-la knockout muscles (n=6); (C) mRNA levels of CDS-1, CLS, Taz, ALCATl, 
MitoPLD and Plscr3 in muscles of wildtype and PGC-1 a knockout mice (n=7). Graph 
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represents fold-changes relative to wildtype mice. Values are representative of means+/-
SEM; p<0.05; * vs. control or wildtype. 
Figure 8. Relative mRNA levels of CL metabolisms enzymes. CL synthesis enzymes CDS-
1 and CLS; CL remodelling enzymes Taz and ALCATl; and OMM CL proteins 
MitoPLD and Plscr3 in (A) young rats (n=12); and (B) wildtype mice (n=7); *vs. CDS-1, 
p<0.05; p<0.05; D vs ALCATl, p<0.05; # vs MitoPLD, p<0.05. Values are 
representative of means+/-SEM. 
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Future Work 
1) We found that the conditions we placed upon the observed skeletal muscles to 
result in altered CL content. It would also be of interest to explore the 
peroxidation levels within these tissues, by isolating CL and utilizing a lipid 
peroxidation measurement, such as the TBARs assay. 
2) Our data revealed that the transcriptional coactivator PGC-1 a is involved in the 
regulation of two CL metabolism transcripts: CDS-1 and ALCATl. Alas, we are 
un.able to comment through which transcriptional machinery the coactivator is 
acting, based on our current results. To explore this, we will measure the effect of 
PGCl-a.-mediated transcriptional alteration of CDS-1 or ALCATl promoter 
activity on different truncations of their respective promoters. 
3) The generation of ALCATl knockout mice has piqued our interest regarding 
future work. More specifically, measuring the levels of other CL remodelling 
genes in the absence of ALCAT 1 will shed light on whether these genes regulate 
the expression of one another. It would also be intriguing to examine whether any 
improvements in exercise performance occur, without the presence of the 
pathological CL remodeller. 
4) Analyses of Taz knockout mice have ~covered similar maladies as those in 
Barth Syndrome patients, such as malfunctioning mitochondria within cardiac and 
skeletal muscles. It would be of interest to explore whether chronic muscle use is 
able to rescue the functional deficits within skeletal muscle lacking Taz. 
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Appendix A 
Data and Statistical Analyses 
r 
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Table lA: COX Activi following 7 days of CCA 
Cytochrome c Oxidase acthity 
(U/g muscle) 
n 
7 day 7 day 
control CCA 
5.83 9.82 
2 6.71 8.49 
3 7.87 12.24 
4 10.49 14.34 
5 9.27 13.89 Paired t test 
6 11.43 13.64 Control w. 7 day CCA 
7 18.94 Two-tailed P value < 0.0001 
8 11.00 t = 8.87 
df=7 
Table lB: COX Activi following 7 days of denervation 
Cytochrome c Oxidase activity 
(U/g muscle) 
n 
7 day 7 day 
control denenated 
1 7.37 6.15 
2 8.95 6.87 
3 8.26 5.18 
4 11.26 8.44 
5 7.84 5.34 Paired t test 
6 9.83 5.36 Control w. 7 day denenated 
7 10.76 6.02 Two-tailed P value = 0.0002 
8 7.45 4.21 t = 7.31 
df=7 
Table lC: COX Activi ~f PGC-la Knockout mice 
Cytochrome c Oxidase activity 
(U/g muscle) 
n Wildtype Knockout 
1 11.08 4.91 
2 8.61 5.17 
3 4.86 3.14 
4 9.04 6.95 
Unpaired t test 
Wildtype w. Knockout 
Two-tailed P value = 0.04 
t = 3.325 
df=3 
l' 
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Table lD: COX Activi 
Cytochrome c Oxidase activity (U/g muscle) 
n 
Young YoungCCA Aged AgedCCA 
Control Control 
1 12.00 18.04 10.75 13.41 
2 9.20 ·11.10 13.48 19.36 
3 16.55 18.04 12.01 16.14 
4 19.37 21.69 12.41 18.77 
5 9.69 22.70 13.69 20.24 
6 14.39 18.77 12.86 16.44 
7 10.37 19.17 9.31 15.15 
8 11.06 18.84 8.13 12.46 
9 12.83 19.37 11.56 13.68 
10 13.33 18.26 7.26 10.96 
llx!±!slll 
Two-Way ANOVA-Young vs. Aged 
Source of Variation P value summary Significant? 
Interaction ns No 
Age * Yes 
Stimulation *** Yes 
Bonferroni posttests- Young vs. Aged 
Aee Difference t P value Summary 
Young 6.379 7.656 P<0.001 *** 
Aged 4.515 5.419 P<0.001 *** 
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Table 2A: Cardioli in content following 7 days of CCA 
Cardiolipin Content 
(µmol/g muscle) 
n 
7 day 7 day 
control CCA 
1 0.4188 0.6792 
2 0.492 0.5248 
3 0.428 0.426 
4 0.223 0.697 Paired t test 
5 0.259 0.416 Control w. 7 day CCA 
6 0.502 0.469 Two-tailed P value = 0.053 
7 0.4898 0.942 t= 2.405 
df=6 
Table 2B: Cardioli in content following 7 days of denervation 
Cardiolipin Content 
(µmol/g muscle) 
n 
8 day 8 day 
control denerwted 
1 1.05 0.55 
2 0.56 0.4 
3 0.73 0.35 
4 0.53 0.45 Paired t test 
5 0.84 0.51 Control w. 8 day denerwte 
6 1.14 0.43 Two-tailed P value = 0.0079 
7 0.66 0.51 t =3.907 
loE/.6!±lotm~I df=6 
Table 2C: Cardioli in content of PGC-la knockout mice 
Cardiolipin Content 
AO Fluorescence 
PGC-la PGC-la 
n 
Wil Knockout 
1 78.82 76.19 
2 72.05 71.8 
3 78.69 89.68 Unpaired t test 
4 80.83 72.85 Wildtype w. Knockout 
5 58.43 61.44 Two-tailed P value = 0.6607 
6 41.41 59.36 t = 0.4522 
~ft±!sJi f4sltl±tisl df= 10 
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Table 3: mRNA ex ression of CL metabolism enzymes following CCA 
CDS-1 mRNA expression (dCI) 
n 
7 day 7 day 
control CCA 
1.11 1.59 
2 0.66 2.25 
3 1.04 2.75 
4 1.01 2.46 
5 1.80 4.91 Paired t test 
6 0.54 1.23 Control vs. 7 day CCA 
7 0.69 1.12 Two-tailed P value = 0.0083 
8 0.41 0.70 t =3.638 
tol9)1i:joiifiJ flliilf±iof4tJ df=7 
CIS mRNA expression (dCI) 
n 
7 day 7 day 
control CCA 
1 10.24 11.07 
2 9.03 . 9.06 
3 12.76 7.92 
4 22.34 23.12 
5 52.86 49.69 Paired t test 
6 19.44 21.40 Control vs. 7 day CCA 
7 25.80 13.21 Two-tailed P value = 0.42 
8 11.30 15.48 t =0.86 
lifsisqi\tsJ1i df=7 
Taz mRNA expression (dCI) 
n 
7 day 7 day 
control CCA 
1 77.43 35.30 
2 37.71 31.21 
3 70.81 24.46 
4 91.50 70.14 
5 213.92 105.49 Paired t test 
6 76.19 139.97 Control vs. 7 day CCA 
7 59.61 105.50 Two-tailed P value = 0.50 
8 10.86 16.79 t =0.71 
. f4>j1ioM1f6\iJii df=7 
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ALCATl mRNA expression (dC1) 
n 
7 day 7 day 
control CCA 
1 5.00 6.48 
2 7.66 3.49 
3 9.50 6.26 
4 5.92 5.26 
5 6.87 1.33 Paired t test 
6 5.71 6.24 Control w. 7 day CCA 
7 4.77 3.43 Two-tailed P value= 0.0472 
8 11.48 5.55 t =2.403 
df=7 
MitoPLD mRNA expression (dC1) 
n 
7day 7 day 
control CCA 
1.32 0.87 
2 4.28 2.55 
3 0.83 1.04 
4 11.97 3.49 
5 Paired t test 
6 3.87 1.13 Control w. 7 day CCA 
7 2.74 1.26 Two-tailed P value = 0.049 
8 14.49 9.79 t =2.46 
df=6 
Plscr3 mRNA expression (dCf) 
n 
7 day 7day 
control CCA 
1 148.30 165.12 
2 31.95 78.39 
3 77.31 221.78 
4 112.45 195.13 
5 170.24 275.00 Paired t test 
6 121.15 136.28 Control w. 7 day CCA 
7 89.96 243.90 Two-tailed P value = 0.006 
8 52.38 88.40 t = 3.85 
df=7 
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Table 4: mRNA ex ression of CL metabolism enzymes following denervation 
CDS-1 mRNA expression (dCI) 
n 
7 day 7 day 
control denervated 
0.004 0.008 
2 0.005 0.016 
3 0.003 0.015 
4 
5 0.002 0.010 Paired t test 
6 0.003 0.014 Control w. 7 daydenerwted 
7 0.005 0.013 Two-tailed P value = 0.0002 
8 0.004 0.015 t = 8.329 
df=6 
CLS mRNA expression (dCT) 
n 
7 day 7 day 
control denervated 
1.60 2.58 
2 1.18 1.13 
3 0.45 1.05 
4 0.60 0.87 
5 0.35 0.62 Paired t test 
6• 0.88 1.98 Control w. 7 day denervated 
7 Two-tailed P value = 0.049 
8 3.83 6.47 t =2.449 
df=6 
Taz mRNA expression (dCI) 
n 
7 day 7 day 
control denervated 
1 6.70 6.14 
2 3.94 3.13 
3 2.33 2.08 
4 1.20 1.33 
5 0.95 1.16 Paired t test 
6 2.31 4.33 Control w. 7 day denervated 
7 6.38 6.64 Two-tailed P value = 0.42 
8 12.92 14.25 t =0.86 
llx!±!s!41 ltl~9lftE41 £41s·sl±l•l~I df=7 
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ALCATl mRNA expression (dCI) 
n 
7 day 7 day 
control denervated 
9.37 49.24 
2 32.44 83.99 
3 3.77 14.12 
4 4.13 15.13 
5 25.09 52.26 Paired t test 
6 4.19 15.40 Control w. 7 day denervated 
7 10.49 49.06 Two-tailed P value = 0.0036 
8 15.03 82.92 t=4.3 
llit±!s)ill df=7 
MitoPLD mRNA expression (dCI) 
n 
7 day 7day 
control denervated 
0.15 0.06 
2 0.06 0.07 
3 0.02 0.03 
4 0.02 0.01 
5 0.00 0.02 · Paired t test 
6 0.04 0.12 Control w. 7 day denervated 
7 0.58 0.12 Two-tailed P value = 0.39 
8 t = 0.91 
df=7 
Plscr3 mRNA expression (dC1) 
n 
7 day 7 day 
control denervated 
1 7.37 6.15 
2 8.95 6.87 
3 8.26 5.18 
4 11.26 8.44 
5 7.84 5.34 Paired t test 
6 9.83 5.36 Control w. 7 day denervated 
7 10.76 6.02 Two-tailed P value = 0.046 
8 7.45 t = 2.42 
df=7 
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Table 5: mRNA ex ression of CL metabolism e mes following CCA and aging 
.--~~~~~~--~~~~~~~~~~~~-----. 
CDS-1 mRNA expression (dCI) 
n 
Young Young Aged Aged 
Control CCA Control CCA 
1 0.007 0.030 0.006 0.022 
2 0.004 0.011 0.009 0.011 
3 0.006 0.026 0.012 0.011 Two-Way ANOVA- Young vs. Aged 
4 0.004 0.010 .0.003. 0.002 Source of Variation P~lue Significant? 
5 0.005 0.006 0.006 0.008 Interaction ns No 
6 0.004 0.019 0.024 Age ns No 
Stimulation ** Yes 
Bonferroni posttests- Young vs. Aged 
Age Difference t P value Summary 
Young 0.01208 3.502 P<0.05 * 
Aged 0.005804 1.683 P>0~05 ns 
~ mRNAexpression (dCI) 
n 
Young Young Aged Aged 
Control CCA Control CCA 
1 4.09 2.62 3.67 5.52 
2 1.47 1.37 0.88 0.93 
3 1.27 0.94 l.03 0.85 Two-Way ANOVA- Young vs. Aged 
4 1.30 1.14 0.58 0.90 Source of Variation Pwlu Significant? 
5 2.57 5.02 3.32 2.73 Interaction ns No 
6 l.05 0.72 0.82 0.82 Age ns No 
Stin1.1lation ns No 
Bonferroni posttests- Young vs. Aged 
Age Difference t P value Summary 
Young 0.008615 0.01929 P>0.05 ns 
Aged 0.2416 0.541 P>0.05 ns 
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Taz mRNA expression (dCI) 
Young Young Aged Aged 
n 
Control CCA Control CCA 
1 11.61 6.70 4.23 6.52 
2 10.39 7.14 4.57 4.41 
3 Two-Way ANOVA- Young vs. Aged 
4 2.85 3.37 1.90 2.28 Source of Variation PwluE Significant? 
5 6.55 15.68 1.82 1.95 Interaction ns No 
6 3.23 4.32 0.66 0.79 Age * Yes 
Stirrulation ns No 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary. 
Young 0.5154 0.295 P>0.05 ns 
Aged 0.5558 0.3182 P>0.05 ns 
AI.CATI mRNA expression (dCI) 
n 
Young Young Aged Aged 
Control CCA Control CCA 
4.43 2.88 5.83 3.85 
2 6.01 2.21 3.91 3.14 
3 3.24 2.84 3.40 5.51 Two-Way ANOVA- Young vs. Aged 
4 3.27 2.70 3.34 3.39 Source of Variation Pwlu~ Significant? 
5 4.05 2.73 3.68 2.64 Interaction ns No 
6 4.08 2.34 2.69 3.03 Age ns No 
Stimllation * Yes 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young -1.565 2.918 P<0.05 * 
Aged -0.2146 0.3999 P>0.05 ns 
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MitoPLD mRNA expression (dCI) 
Young Young Aged Aged 
n 
Control CCA Control CCA 
1 0.20 0.09 0.28 0.20 
2 O.()<) 0.07 0.o7 0.()<) 
3 0.06 0.03 0.04. 0.03 Two-Way ANOVA- Young vs. Aged 
4 0.11 0.10 0.07 0.10 Source of Vari:ation P~lue Significant? 
5 0.15 0.09 0.()<) 0.()<) Interaction * Yes 
6 0.18 0.09 0.07 0.14 Age ns No 
Stimulation ns No 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young -0.05628 3.052 P<0.05 * 
Aged 0.004078 0.2211 P>0.05 OS 
Plscr3 mRNA expression (dC1) 
n 
Young Young Aged Aged 
Control CCA Control CCA 
l 1.21 2.39 3.04 3.02 
2 2.74 4.19 2.33 2.07 
3 1.01 1.38 1.31 0.97 Two-Way ANOVA- Young vs. Aged. 
4 1.21 2.38 1.38 1.53 Source of Variation Pwlue Significant? 
5 Interaction * Yes 
6 0.68 4.08 0.75 0.85 Age OS No 
Stinulation ns No 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young 1.601 3.462 P<0.05 * 
Aged -0.08365 "0.1809 P>0.05 OS 
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Table 6: mRNA expression of CL enzymes following denervation and aging 
CDS-1 mRNA expression (dC1) 
Young Young Aged Aged 
n Control Denenated Control Denenated 
0.12 0.22 0.15 0.12 
2 0.22 0.46 0.11 0.08 
3 0.12 0.22 0.11 0.13 Two-Way ANOVA 
4 0.05 0.16 0.14 0.11 Source of Variation Pvalue Significant? 
5 0.09 0.18 0.30 0.36 Interaction ** Yes 
6 0.06 0.09 0.10 0.27 Age ns No 
Denervation ** Yes 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young 0.1119 3.627 P<0.01 ** 
Aged 0.02655 0.8607 P>0.05 ns 
CIS mRNA expression (dCI) 
n 
Young Young Aged Aged 
Control Denenated Control Denenated 
1 1.51 2.45 1.12 2.05 
2 0.95 1.81 1.29 1.60 
3 0.71 1.02 0.71 0.92 Two-Way ANOVA 
4 0.55 0.82 0.88 1.39 Source of Variation Pvalue Significant? 
5 1.22 1.63 1.00 1.31 Interaction ns ·No 
6 1.39 2.17 1.22 1.26 Age ns No 
X±SE 1.05 ± 0.15 1.65 ±2.59 1.03 ±0.88 1.42 ±0.15 Denervation *** Yes 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young 0.5975 4.821 P<0.01 **' 
Aged 0.3826 3.087 P<0.05 * 
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Taz mRNA expression (dCI) 
n 
Young Young Aged Aged 
Control Denenated Control Denenated 
1 5.92 4.95 4.12 4.10 
2 2.79 3.07 3.14 2.99 
3 2.94 2.28 2.76 2.65 Two-Way ANOVA 
4 2.73 3.29 3.56 4.11 Source of Variation P value Significant? 
5 3.52 4.59 2.86 2.71 Interaction ns No 
6 Age ns No 
llx!±!sil !1'518f~ B!6~'1'±,0:l4~~ l§f'lt'J~±,0"2~ l§~llr±~01§10] Denervation ns No 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young 0.05587 0.1966 P>0.05 ns 
Aged 0.02729 0.09605 P>0.05 ns 
ALCATl mRNA expression (dC1) 
n 
Young Young Aged Aged 
Control Denenated Control Denenated 
1 1.55 4.01 1.87 1.75 
2 1.84 4.09 2.03 2.14 
3 1.21 6.51 1.51 1.76 Two-Way ANOVA 
4 0.42 3.54 0.95 1.39 Source of Variation Pvalue Significant? 
5 0.49 2.11 0.71 1.20 Interaction *** Yes 
6 3.35 7.02 0.76 0.65 Age * Yes 
Denervation *** Yes 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young 3.071 7.992 P<0.001 *** 
Aged 0.1762 0.4585 P>0.05 ns 
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MitoPLD mRNA expression (dC1) 
Young Young Aged Aged 
n Control Denenated Control Denenated 
1 0.027 0.031 0.016 0.027 
2 0.013 0.017 0.031 0.009 
3 0.009 O.Q22 0.004 0.013 
4 0.017 0.019 0.011 0.018 Two-Way ANOVA 
5 0.007 0.011 0.008 0.005 Source of Variation P vailue Significant? 
6 0.014 0.013 0.008 0.009 Interaction ns No 
Age ns No 
Denervation ns No 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young 0.004509 1.211 P>0.05 ns 
Aged 0.0004705 0.1263 P>0.05 ns 
Plscr3 mRNA expression (dCI) 
n 
Young Young Aged Aged 
Control Denenated Control Denenated 
1 4.092173 4.675187 3.926263 4.591325 
2 2.005295 2.131153 2.574178 2.710416 
3 2.14033 3.281365 2.010223 2.517745 Two-Way ANOVA 
4 1.723421 2.302112 2.392681 3.142764 Source of Variation Pvalue Significant? 
5 1.405274 1.750704 1.057099 1.389272 Interaction ns No 
6 1.035019 1.166221 1.28445 Age ns No 
lit±l14 t!o~J±loltiJ Denervation *** Yes 
Bonferroni posttests- Young vs. Aged 
Age Difference t Pwlue Summary 
Young 0.005796 4.613 P<0.01 ** 
Aged 0.004182 3.328 P<0.05 * 
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Table 7: mRNA ex ression of CL metabolism enzymes in PGC-la knockout mice. 
CDS-1 mRNA expression (dCI) 
n Wildtype Knockout 
0.16 0.10 
2 0.23 0.09 
3 0.51 0.16 
4 0.46 0.15 Unpaired t test 
5 0.39 0.13 Wildtype w. Knockout 
6 0.27 0.10 Two-tailed P value = 0.0023 
7· 0.20 0.08 t=5.053 
df=6 
CI.S mRNA expression (dCI) 
n Wildtype Knockout 
5.20 8.11 
2 8.72 7.12 
3 9.78 11.45 
4 11.79 11.08 Unpaired t test 
5 9.07 10.90 Wildtype w. Knockout 
6 11.59 8.40 Two-tailed P value = 0.58 
7 10.58 14.85 t =0.5666 
df= 12 
Taz mRNA expression (dC1) 
n Wildtype Knockout 
12.43 13.21 
2 13.79 12.56 
3 27.35 29.28 
4 35.38 32.79 Unpaired t test 
5 139.48. 160.00 Wildtype w. Knockout 
6 167.98 117.55 Two-tailed P value = 0.90 
7 26.24 28.36 t =0.1254 
rot!s!±l~E41 ~6!z~l±l~!ol df=12 
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ALCATl mRNA expression (dCI) 
n Wildtype Knockout 
1 1.11 3.26 
2 ' 1.03 2.39 
3 1.20 1.56 
4 1.55 3.90 Unpaired t test 
5 2.84 4.31 Wildtype w. Knockout 
6 2.90 3.47 Two-tailed P value = 0.009 
7 1.77 3.59 t =3.098 
df= 12 
MitoPLD mRNA exf>ression (dCI) 
n Wildtype Knockout 
1 0.06 0.07 
2 0.19 0.14 
3 0.85 0.47 
0.60 0.44 4 Unpaired t test 
1.18 1.44 5 Wildtype w. Knockout 
6 2.26 1.67 Two-tailed P value= 0.70 
7 1.10 1.01 t = 0.3889 
Xi~(S,E> .. : .. ·. o,.~'.~f#h~j;~:~··::, '·i1:g;1~'#!'9:~·~~;'~·; df = 12 
Plscr3 mRNA expression (dCI) 
n Wildtype Knockout 
1 6.93 7.48 
2 9.54 7.15 
3 22.22 24.64 
4 27.33 23.98 Unpaired t test 
5 17.08 20.73 Wildtype w. Knockout 
6 19.61 17.49 Two-tailed P value = 0.99 
7 10.28 11.36 t =0.005 
df= 12 
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Table 8: Relative mRNA levels of CL metabolism enzymes in rat. 
n CDS-1 
I 0.007 
2 0.004 
3 0.006 
4 0.004 
5 0.005 
6 0.004 
7 0.015 
8 0.035 
9 0.184 
10 0.040 
11 0.069 
12 0.015 
lft±!sll 
One way analysis of variance 
Control w. 7 day CCA 
P value < 0.0001 
mRNA levels in rat muscle (dCT) 
CLS Taz ALCATl 
2.565 4.588 4.429 
1.387 8.529 6.007 
1.472 9.875 3.244 
1.055 1.706 3.415 
1.272 1.908 3.050 
1.298 2.733 3.084 
1.105 5.472 2.001 
1.189 3.422 2.311 
0.764 2.443 1.689 
0.859. 2.749 0.406 
1.261 1.499 0.384 
0.858 1.164 0.880 
ANOVATable SS df 
Between 282 6 
Within 206.2 77 
Total 488.2 83 
Tukey's Multiple Comparison Test Mean DifT. q Pwlue 
CDS-1 w CLS -1.225 2.592 P>0.05 
CDS-1 w Taz -3.808 8.062 P<0.001 
CDS-1 w ALCATl -2.543 5.382 P<0.01 
CDS-1 w. MitoPLD -0.1114 0.2359 P>0.05 
CDS-1 w Plscr3 -2.365 5.007 P<0.05 
CLS w Taz -2.584 5.469 p <0.01 
CLSwALCATl -1.318 2.79 P>0.05 
CLS w MitoPLD 1.113 2.357 P>0.05 
CLS w Plscr3 -1.14 2.414 P>0.05 
Tazw ALCATl 1.266 2.679 P>0.05 
Taz w MitoPLD 3.697 7.826 P<0.001 
Taz w Plscr3 1.443 3.055 P>0.05 
ALCATl w MitoPLD 2.431 5.146 p <0.01 
ALCATl w Plscr3 0.1775 0.3756 P>0.05 
MitoPLD w Plscr3 -2.254 4.771 P<0.05 
MitoPLD 
0.104 
0.174 
0.081 
0.094 
0.468 
0.105 
0.020 
0.165 
0~094 
0.265 
0.069 
0.086 
MS 
47.01 
2.678 
Plscr3 
3.606 
4.243 
3.916 
1.299 
1.730 
1.340 
2.999 
2.522 
2.314 
2.711 
1.452 
0.640 
91 
Table 9: Relative m,RNA levels of CL metabolism enzymes in mouse. 
mRNA levels in mouse muscle (dCT) 
n CDS-1 CIS 
1 4.814 48.475 
2 7.233 74.283 
3 13.263 171.218 
4 15.622 175.923 
5 16.311 109.352 
6 9.583 114.074 
7 10.597 178.577 
lx!±!sJEj 
One way analysis of variance 
Control w. 7 day CCA 
P value< 0.0001 
Tukey's Multiple Compirison Test 
CDS-1 w CIS 
CDS-1 w TAZ 
CDS-1 w ALCATl 
CDS-1 w .MitoPLD 
CDS-1 w Plscr3 
CISwTAZ 
CIS w ALCATl 
CIS w .MitoPLD 
CIS w Plscr3 
TAZwALCATl 
TAZ w .MitoPLD 
TAZw Plscr3 
ALCATl w .MitoPLD 
ALCATl w Plscr3 
MitoPLD w Plscr3 
Taz 
115.955 
102.278 
478.599 
527.762 
1680.761 
1653.444 
442.776 
ANOVATable 
Bemeen 
Within 
Total 
Mean DitT. q 
-0.1135 0.9955 
-0.7442 6.528 
-0.01122 0.09839 
-0.0005018 0.004401 
-0.2053 1.801 
-0.6307 5.532 
0.1023 0.8971 
0.113 0.9911 
-0.09182 0.8054 
0.733 6.429 
0.7437 6.523 
0.5389 4.727 
0.01072 0.09399 
-0.1941 1.703 
-0.2048 1.796 
ALCATl MitoPLD 
10.321 0.527 
8.806 1.578 
21.001 14.826 
23.177 8.948 
34.224 14.164 
28.525 22.260 
29.890 18.633 
Rif±jill 
SS elf MS 
0.2381 5 0.04761 
0.1384 36 0.003846 
0.3765 41 
Pwlue 
P>0.05 
P<0.001 
P>0.05 
P>0.05 
P>0.05 
P<O.ot 
P>0.05 
P>0.05 
P>0.05 
P<0.001 
P<0.001 
P<0.05 
P>0.05 
P>0.05 
P>0.05 
Plscr3 
64.610 
81.287 
388.729 
407.765 
205.838 
193.018 
173.390 
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Appendix B 
·Experimental protocols 
---- --.-
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Implantable stimulation unit-surgical procedure 
Sterilize all surgical tools prior to commencing the surgical procedures outlined below 
and also keep lab bench as sterile as possible by wiping it down thoroughly with ethanol. 
1. Shave the skin over the left flank (between the last rib and the pelvis) and over the left 
hindlimb and wipe with iodine. 
Shave 
i l'. Imp1aatable 
! • i• '. ~ 'I . . Stnmmla~Jrc.~;nt TT mt 
I ·:y 
! . lUectro 
T 
'\ 
2. Make a skin incision midway between the most distal rib and the pelvic girdle with the 
rat lying on its side in a vertical direction that extends from approximately 30-40% (10-
20mm) of the circumferential distance from the ·umbilicus to the spine (the strategy is to 
make the incision far enough from the spine to penetrate the less complex musculature 
but to try to minimize the extent of the incision on the ventral surface of the animal to 
, avoid post-surgery dragging of the wound during locomotion). 
---------~~--
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3. Tunnel a subcutaneous passage from the left hindlimb to the left flank using the 
tunneler. 
Tunnele 
4. Once the skin incision has been made on the left flank tunneling has been performed, 
lift the abdominal wall (with forceps) and snip horizontally through the abdominal 
musculature. This incision only needs to be large enough for the stimulation· unit to be 
squeezed through but keep the Dacron mesh upwards, so that it can be incorporated into 
the suture line that closes the abdominal musculature. 
95 
5. Suture the abdominal wall With 5.0 silk and incorporate the Dacron mesh into the 
suture line (about 3-4 independent sutures). Keep the electrodes to one side of the suture 
line. 
6. Affix the electrodes to the tunneler by folding over the end-piece (one with the slot) of 
the tunneler and carefully tunnel the electrodes from the left flank to the left hindlimb 
being sure not to damage the electrodes. 
7. Make small horizontal cut into the underlying left hindlimb muscle (biceps femoris) 
and blunt through the muscle to expose the peroneal nerve (exactly the same as our 
external stimulation protocol). Once the nerve has been exposed, use 4 retractors gain a 
larger exposure of the nerve and underlying musculature. 
8. Electrodes contain a loop on the end of the lead. Place needle of suture through the_ 
loop and tie a knot that attaches the suture to the loop of the electrode. 
8. Using forceps (with sharp teeth), pinch a small amount (between 0.5-1.0 mm) of 
muscle that is flanking the peroneal nerve. Place needle through the pinched muscle 
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section and proceed to tie down the loop section of the electrode to the underlying 
muscle. Once the loop section has been tied down, tie down a proximal section (3-4mm 
from the electrode loop) of the electrode to another thin section of muscle that is 3-4mm 
away from the loop portion. 
9. Repeat steps 7 and 8 for the other electrode lead but suture this electrode on the other 
side of the peroneal nerve. Test the sJimulation unit by turning the unit on with the digital 
stroboscope (ON-2 Flashes, OFF-1 Flash). Palpate the muscle to ensure adequate 
stimulation. 
10. Once both electrodes are sutured to the underlying muscle, the incision is closed with 
3-5 independent sutures (5.0 silk) and the skin closure is stapled. 
97 
I I 
. Surgery for denervation of skeletal muscle 
1. Sterilize surgical instruments in autoclave machine for 20 minutes. 
2. Anaesthetize rat with 0.2 mls/1 OOg body weight of Ketamine/Xylazine. 
3. Shave animal's right hindlimb close to the skin. 
4. Wipe the shaved area with 1 % topical iodine antiseptic solution. 
5. Make a 2 cm incision in the skin approximately 1 cm posterior and 1 cm inferiior 
to the knee. 
6. Carefully blunt dissect through the exposed superficial muscle until the common 
peroneal nerve is visualized. This nerve innervates the tibialis anterior (TA) and 
extensor digitorum longus (EDL) muscles. 
7. Cut out a small 5mm section of the nerve. This ensures that the nerve endings 
will not regenerate during the experiment and thus effectively denervates the TA 
and EDL muscles. 
8. Inject a small volume (-0.lmls) of sterile ampicillin in the local incision site. 
9. Using the 5 .0 surgical silk, suture close the superficial muscle tear. Seal the 
overlying skin on the hindlimb using s_urgical staples. 
10. Monitor the animal over the next 24 hours to ensure recovery. The animal is foee 
to move about the cage and feed/drink ad libitum. 
11. Recovering animals are given amoxicillin in their drinking water (0.025% w/v) 
for 1 week after surgery. 
Peroneal nerve sectioned 
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Cytochrome c oxidase (COX) assay for microplate reader 
Theory 
Cell extract containing cytochrome c oxidase is added to the test solution containing fully 
reduced cytochrome c-. The rate of cytochrome c oxidation is measured over time as a 
reduction in: absorbance at 550 nm. The reaction is carried out at 30° C. 
Reagents 
1. Horse Heart Cytochrome c (Sigma, C-2506) 
2. Sodium Dithionite 
3. 100 mM K-Phosphate Buffer (KP04;pH to 7.0) 
-make and mix equal proportions of 0.1 M KH2P04 and 0.1 M K1HP04.3H20 
4. 10 mM K-Phosphate Buffer 
-dilute 100 mM K-Phosphate Buffer 1 :10 with ddH20 
Procedure 
1. Immediately following the completion of the enzyme extraction protocol from 
cells, proceed to making Test Solution. Add the following to a scintillation vial: 
- weigh out 20 mg of horses heart cytochrome c 
- add 1 ml of 10 mM KP04 buffer and fully dissolve cytochrome c 
- make up a small volume of 10 mg/ ml sodium dithionite- 10 mM KP04 stock 
solution (Note: make fresh each experiment and use within 20 minutes) 
- add 40 µl of dithionite stock solution to the Test Solution and observe the red to 
orange colour change 
- add 8 ml of ddH20 
- add 1 ml of 100 mM KP04 buffer (Note: the Test Solution becomes light sensitive at 
this step; make sure to the cover vial with aluminum foil). 
2. Add 300 µl of Test Solution into 4-8 wells of a 96-weJl microplate and incubate at 
30°C fot 10 minutes to stabilize the temperature and absorbance. 
1. Open KC4 plate reader program. Select CONTROL icon, then PRE-HEATING 
tab, enter 30°C and select ON (Do not run assay until KC4 temperature has 
reached 30°C). 
2. Set-up of COX activity protocol on computer. 
3. Select WIZARD icon, then READING PARAMETERS icon. 
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• Select Kinetic for Reading Type. 
• Select Absorbance for Reader and 550 nm for wavelength (drop-down). 
• Select Sweep for Read Mode. 
• Select 96 Well Plate (default) for Plate Type. 
• Enter first and last well to be read (eg. Al and A4 if reading 4 samples 
simultaneously). 
• · Select Yes and Pre-heating and enter 30 for Temperature Control. 
• For Shaking enter 0 for both intensity and duration (shaking 1s not 
necessary and it will delay the first reading). 
• Do not select either of the two options for Pre-reading. 
• Click on the KINETIC ... rectangular tile to open the Kinetic window. 
• Enter run time (1 minute is recommended) and select MINIMUM for 
Interval time (under these conditions the minimum Interval time should be 
3 seconds). 
• Select Allow Well Zoom During Read to see data in real time (optional). 
• Under Scales, checkmarks should appear for both Auto check boxes. Do 
not select Individual Well Auto Scaling. 
• Press OK to return to Reading Parameters window. Press OK to return to 
Wizard window. Press OK. Do not save the protocol. 
4. Set the micropipette to 225 µland secure 4-8 tips on the white projections (make 
sure they are on tight and all the same height). 
5. In a second, clean 96 well plate, pipette samples into 4-8 empty wells. (start with 
Al). Recommended volumes: 65 µl of enzyme extract from C2Cl2 cells. 
6. Remove microplate with Test Solution from the incubator (as long as it has been 
incubating for 10 minutes). Place this plate beside the plate with the sample 
extracts in it. 
7. On KC4 program, select the READ icon and press the START READING icoltl, 
then press the READ PLATE button. A box will appear that says, "Insert plaite 
and start reading". Do not press OK yet, but move the mouse so that the cursor 
hovers over the OK button. 
8. Using the micropipette (set to 225 µl) carefully draw up the Test Solution. Make 
sure the volume is equal in all the pipette tips, and that no significant air bubbl<::s 
have entered any of the tips. 
9. Pipette the Test Solution into the wells with the sample extracts (the second plate). 
As soon as all the Test Solution has been expelled from the tips (do not wait for 
the second push from the multi pipette), place the plate onto the tray of the plate 
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reader and with the other hand on the mouse, press the OK button. (Speed at thJs 
point is paramount, as there is an unavoidable latency period between the time of 
pressing the OK button and the time of the firs~ reading.) 
10. If desired, add 5 µl KCN to one of the wells to measure any absorbance changes in 
the presen~e of the CYTOX inhibitor. 
11. Once reading is complete, hold the CTRL key on the keyboard, and use the mouse 
to click once on each of the squares corresponding to a well that had sample in it. 
Once all the desired wells have been highlighted by a black sqt1are (up to a 
maximum of 8 wells), let go of the CTRL key and a large graph will appear with 
lines on it representing each sample. 
12. To obtain the rate of change of absorbance over different time periods, select 
Options and enter the amount of time for which you would like a rate of change of 
absorbance to be calculated. The graph, along with one rate (at whichever time 
interval is selected) for each sample can be printed on a single sheet of paper, and 
the results can be saved. 
13. The delta absorbance will appear in units of mOD/min and the number given will 
be negative. Convert this to OD/min by dividing by 1000 and omit the negative 
sign in the calculation. ( eg. if Mean V: -3.94.8 mOD/mn, then use 0.395 OD/min) 
CALCULATION: 
CYTOX activity= mean dealta absorbance/ minute x total volume (ml) x 1000 
18.5 (µmol/ml extinction coeff.) x sample volume (ml) x total µg/ well 
Example Calculation: 
55 µl of enzyme extraction 
230 µl of Test Solution 
Mean V: -584.30 mOD/mn 
Protein concentration: 3.023 µg/ µl 
Total µg/ well: 151.15 
COX activity= (0.5843)(0.285)(1000) 
(18.5)(0.055)(3.023 x 55) 
COX activity= 0.967 nmol/min/µg protein 
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Mitochondrial isolation 
Reagents 
All buffers are set to pH 7.4 and stored at 4 °C 
- Buffer 1 +ATP 
- Buffer 1 
lOOmMKCl 
5mMMgS04 
5mMEDTA 
Add 1 mM ATP to Buffer 1 
50 mM Tris base 
- Buffer 2 
lOOmMKCl 
5mMMgS04 
5mMEGTA 
50 mM Tris base 
1 mMATP 
- Nagarse protease (Sigma, P-4789) 
10 mg/ml in Buffer 2 
Make fresh for each isolation, keep on ice 
Procedure 
- Resuspension medium 
lOOmMKCl 
lOmMMOPS 
0.2%BSA 
1. Remove the tibialis anterior (TA) muscle from the rat, and put it in a beaker 
containing 5 ml Buffer 1, on ice immediately. 
2. Place TA on a watch glass that is also on ice and trim away fat and connective 
tissue. Proceed to thoroughly mince the muscle sample with forceps and scissors, 
until no large pieces are remaining. 
3. Place the minced tissue in a plastic centrifuge tube and record the exact weight of 
tissue. 
4. Add a 10-fold dilution of Buffer 1 +ATP to the tube. 
5. Homogenize the samples using the Ultra-Turrax polytron with 40% power output 
and 10 s exposure time. Rinse the shaft with 0.5 ml of Buffer 1 + ATP to help 
minimize sample loss. 
6. Using a Beckman JA 25.50 rotor, spin the homogenate at a centrifuge setting of 
800 g for 10 min. This step divides the IMF and SS mitochondrial subfractions. 
The supemate will contain the SS mitochondria and the pellet will contain the 
IMF mitochondria. 
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SS mitochondrial isolation: 
7. Filter the supemate through a single layer of cheesecloth into a second set of 50 
ml plastic centrifuge tubes. · 
8. Spin tubes at 9000 g for 10 min. Upon completion of the spin· ·discard the 
supemate and gently resuspend the pellet in 3.5 ml of Buffer 1 +ATP. Since the 
mitochondria are easily damaged, it is important that the resuspension of the pellet 
is done carefully. 
9. Repeat the centifugation of the previous step (9000 g for 10 min) and discard the 
supemate. 
10. Resuspend the pellet in 200 µl of Resuspension medium, being gentle so as to 
prevent damage to the SS mitochondria. Some extra time is needed during this 
final resuspension to ensure the SS pellet is completely resuspended. 
11. Keep the SS samples on ice while proceeding to islolate the IMF subfraction. 
IMF mitochondrial isolation: 
7. Gently resuspend the pellet (from step 6) in a IO-fold dilution of Buffer 1 +ATP 
using a. teflon pestle. 
8. Using the Ultra-Turrax polytron set at 40% power output, polytron the 
resuspended pellet for 10 s. Rinse the shaft with 0.5 ml of Buffer 1 + ATP. 
9. Spin at 800 g for 10 min and discard the resulting supemate. 
10. Resuspend the pellet in a 10-fold dilution of Buffer 2 using a teflon pestle. 
11. Add the appropriate amount of nagarse. The calculation for the appropriate 
volume is 0.025 mVg of tissue. Mix gently and let stand exactly 5 min. 
12. Dilute the nagarse by adding 20 ml of Buffer 2. 
13. Spin the diluted samples at 5000 g for 5 min and discard the resulting supernate. 
14. Resuspend the pellet in a 10-fold dilution of Buffer 2. Gentle resuspension is with 
a teflon pestle. 
15. Spin the samples at 800 g for 10 min. Upon the completion of the spin, the 
supemate is poured into another set of 50 ml plastic tubes (on ice), and the pellet 
is discarded. 
16. Spin the supemate at 9000 g for 10 min. The supemate is discarded and the pellet 
is resuspended in 3.5 ml of Buffer 2. 
17. Spin samples at 9000 g for 10 min and discard the supemate. 
18. Gently resuspend the pellet in 300 µl of Resuspension medium. 
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Reagents · 
- Extraction buffer 
100 mM Na/K P04 
2mMEDTA 
pH to 7.2 
- 5 X Bradford dye . 
Bradford protein ass8:y 
250 ml 85% Phosphoric acid 
250 ml 100% Ethanol 
500ml ddH20 
0.235 g Coomassie Brilliant Blue 0250 
- Bovine Serum Albumin (BSA) 
2 mg/ml in ddH20 
Procedure 
1. Prepare the test tubes allowing for duplicates of each sample. 
2. Add 95 µl of extraction buffer .to each tube. 
3. Add 5 µl of sample to each tube containing the extraction buffer. 
4. To generate the standard curve, add the following volumes (in µl) of extraction 
buffer: BSA, each in separate tubes- 100:0, 95:5, 90:1.0, 85:15, 80:20, 75:25. 
5. Pipette 5 ml of 1 X Bradford reagent into each tube and mix by gentle vortexing. 
6. In duplicate, add 0.2 ml of each test tube to 96 well plate wells. 
7. Measure absorbance of wells at 595 nm with a microplate reader. 
8. Calculate the protein concentration of each sample using the standard curve. 
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Flow cytometry 
Reagents 
Resuspension Buffer 
lOOmMKCl 
lOmMMOPS 
0.2%BSA 
5 µM NAO solution 
2.5 µL of 1 mM NAO 
500 µL of resuspension buffer 
Procedure 
1. Obtain 100 mg of isolated mitochondria 
a. Spin down at 9000 g for 3 minutes at room temperature 
b. Dump supernatant fraction 
c. Resuspend in 500 µL of 5 µNAO 
d. Leave at room temperature for 15 minutes 
2. Wash 
a. Spin down at 9000 g for 3 minutes at room temperature 
b. Dump supernatant fraction 
c. Resuspend in 300 µL of resuspension buffer 
Samples now ready for Flow Cytometer, observed at 50 000 events. 
Gating: Histogram: 
Mitochondrial population Fluorescence ofNAO stain 
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The mitochondrial dye Mi to Tracker Green FM was used to discriminate between 
mitochondria and debris, and thus gate the R2 region. 
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RNA Isolation 
Procedure 
1) Homogenize (approximately 30 sec.@ 30-40% power) tissues (200 mg) at 
30% in 2 ml Tri-reagent in a 13 ml Sarstedt tube; 
OR 
Homogenize (approximately 30 sec.@ 30-40% power) tissues (200 mg) at 
30% in 1.25 ml solution D + 1.25 ml phenol+ 0.125 ml 2M sodium acetate 
(pH 4.0) in a 13 ml Sarstedt tube 
**Note: The homogenizer must be sterilized in O. lM NaOH and rinsed in 
sterile water prior to use. Rinse in sterile water between samples. 
2) Let stand for 5 min at room temperature; 
3) Add 0.4 ml chloroform and shake vigorously for 15 sec, let stand for 2-3 min at 
room temperature; 
4) Spin at 12,000 g for 15 min at 4°C; 
5) Transfer aqueous phase to 13 ml Sarstedt tube; 
6) Add 1 ml isopropanol, gently shake, and allow precipitation of RNA for 5-10 min 
at room temperature; 
7) Spin at 12,000 g for 10 min at 4°C; 
8) Remove supernatant fraction and add 0.7 ml 75% ethanol; 
9) Transfer RNA to eppendorf tube; 
10) Rinse 13 ml Sarstedt tube with 0.3 ml 70% ethanol, add to eppendorftube and 
mix by vortexing; 
11) Spin 5 min in eppendorf centrifuge at 4 °C; 
12) Discard supernatant fraction; 
13) Dry pellet under a vacuum in dessicator (DO NOT DRY PELLET WITH 
CENTRIFUGATION UNDER A VACUUM); 
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14) Dissolve pellet in 50-200 µl sterile distilled DEPC water and measure absorbance: 
at 260 nm and 280 nm. 
Reagents 
1. Solution D (Denaturing solution) 
4 M Guanidinium Thiocyanate 
25mM of 1 M stock NaCitrate (pH 7.0) 
N-Lauroyl Sarcosine;Sigma L-5125 (0.5% Sarcosyl) 
ddH20 
125 g 
6.6ml 
1.32 g 
160ml 
**Note: make up solution D and store at RT for up tq 3 months. On the 
day of the experiment, mix 50 ml of Solution D with 0.36 ml ofbeta-
Mercaptoethanol (0.1 M b-MEtOH) 
2. Phenol (Nucleic acid grade) 
a) Melt solid phenol at 68 ° C (cap loose) in HiO; 
b) Add 0.25 g 8-hydroxyquinoline to 250 ml of phenol, mix; 
c) Add 250 ml 1.0 M Tris HCl (pH 8.0) and stir overnight at 4 °C covered in foil 
d) Remove supernatant fraction; 
e) Add 250 ml 0.1 M Tris-HCl containing 0.2 % b-MEtOH (0.178 ml/100 ml for 
S.G. = 1.12) and mix thoroughly; 
f) Allow solution to settle and remove supernatant fraction; 
g) Repeat 2 more times as above or until pH of phenol is> 7.6 (test with pH paper). 
h) Store in 25-50 ml aliquots at -20 ° C. 
3. 2. 0 M Na Acetate (pH 4.0) 
10.88 g/l 00 ml s_terile H20 
4. 75% ethanol in sterile H20 
(75 ml ethanol+ 25 ml dH20) 
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RNA formaldehyde gel 
Reagents 
1. 0.1% SDS (Sodium Dodecyl Sulfate) 
2. 1 Ox MOPS (Morpholinepropanesulfonic acid) 
41.86 g MOPS 
3.72 gEDTA 
900 ml dH20, pH to 7.4 
* make up to 1 L, autoclave 
3. Agarose 
4. Sterile ddH20 
5. 0. 5 mg/ml EtBr (Ethidium Bromide) 
6. RNA Sample Buffer 
100% deionized formamide 
3 7% formaldehyde 
lM MOPS (pH 7.4) 
0.5MEDTA 
100% glycerol 
1 % dyes (10 mg bromphenol blue, lOmg Xylene Cyanol) 
10% SDS 
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Procedure 
1. Prepare the gel and electrophoresis chamber after overnight or 1 hr sterilization 
with 0.1 % SDS; 
2. Rinse the gel plates, electrophoresis chamber, and comb with sterile ddH20, and 
wipe dry; 
Running buffer: 
Small Chamber Large Chamber 
30 ml lOX MOPS 200 ml lOX MOPS 
270 ml Sterile 1800 ml Sterile 
ddH20 ddH20 
1 % Agarose gel: 
Small Gel Large Gel 
0.4 g Agarose 1. 7 g Agarose 
4ml lOXMOPS 17ml lOXMOPS 
34ml Sterile ddH20 144 ml Sterile ddH20 
Weigh, melt, make up volume with 
sterile ddH20 wei2ht and add: 
2 ml 37% 8.5 ml 37% 
Formaldehyde Formaldehyde 
3. Allow gel to cool for 15 minutes, pour, and let gel set for 30 min. Transfer the 
plate with, the gel to an electrophoresis chamber, and place the end with the wells 
at the negative electrode; 
4. Calculate the volumes of RNA and sample buffer required for desired amount of 
RNA; 
Combine in sterile eppendorf tubes: 
RNA.................................................. x µl 
EtBr................................................... 4 µl 
Sample buffer.................................... x µl 
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*Note: use at least a 1: 1 ratio of buffer to RNA volume. (max. volume of 30 µl). 
5. Mix the samples by tapping; 
6. Denature the samples for 65°C for 10 min, quick cool; 
7. Spin down volume briefly in microfuge; 
8. Pipette the entire volume into each well of the gel. 
9. Run the gel ("'80 V) until second dye band, Xylene Cyanol, is 2/3 from the end; 
10. Visualize and photograph the gel under UV light. 
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Reverse transcription: first strand cDNA synthesis 
First-strand cDNA synthesis is performed following the manufacturer's recommendations 
that are outlined below: 
Reagents 
1. total RNA (isolated as described) 
2. Oligo( dT)12-1s 
3. 10 mM dNTPs (dATP, dTTP, dCTP, dGTP; 10 mM each) 
4. Sterile ddH20 
5. RN Ase OUT ( 40 units/ µl) 
6. 0.1 MDTT 
7. 5X First-strand Buffer 
8. SuperScript II RT 
*Note: All reagents except RNA are supplied with the SSII kit from Invitrogen. 
Procedure 
1. Add following components to a nuclease/ RNA-free 500 µl eppendorf: 
Oligo( dT)12-1s 
1 µgofRNA 
dNTPmix 
Sterile ddH20 
lµl 
x µl 
1 µl 
to 20 µl 
2. Heat mixture to 65°C for 5 minutes and quick chill on ice. Collect the contents with a 
quick spin in a tabletop microcentrifuge and then add: 
5X First-strand buffer 4 µl 
O.lMDTT 2·µ1 
RNAse OUT 1 µl 
3. Mix contents of tube gently and incubate at 42°C for 2 minutes. 
4. Add 1 µl (200 units) of Superscript II RT and mix by pipetting gently up and down. 
5. Incubate at 42°C for 50 minutes. 
6. Inactivate the reaction by heating at 70°C for 15 minutes~ 
7. cDNA is ready for use in PCR amplification. 
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Real-time polymerase chain reaction (PCR) 
1. Convert 2 ug of RNA to 2 ug of cDNA {STOCK cDNA) 
2. Diluted STOCK cDNA to 1 :30 (WORKING cDNA) 
-2 uL STOCK cDNA + 58 uL nuclease-free ddH20 
3. Add 10 µg cDNA per well (4 µL of WORKING cDNA) 
For SYBR Green analyses 
1. Primers were diluted to 300 µM (STOCK primers), 
2. Diluted further to 20 µM (WORKING primers) in a separate tube; 
3. In each well, add 
2.5 µL of both forward and reverse primers; 
12.5 µL Quanta PerfeCTa SYBR® Green SuperMix, ROX Master M~x; 
3.5 µL nuclease-free ddH20; 
4 µL of WORKING cDNA. 
For TaqMan analyses 
1. In each well, add 
12.5 µL TaqMan Universal Master Mix; 
1.25 µL the appropriate TaqMan probes; 
7.25 µL nuclease-free ddH20; 
4 µL of WORKING cDNA. 
Total reaction volumes is 25 µL per well. 
Duplicated samples to ensure accuracy. 
Use negative wells to monitor contamination (nuclease-free ddH20 in place of cDNA). 
Check for nonspecific amplification and primer dimers by analyzing melt curves 
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Gene, Type Accession Forward Primer Reverse Primer 
Size(bp) Number 
CDS-I Rat NM Applied Biosystems TaqMan Probe Assay ID Rn00579942_ml 
031242.2 
Lclatl Rat XM Applied Biosystems TaqMan Probe Assay ID Rn01468447_ml 
(ALCATI) 34l>20.4 
Rps12 Rat NM Applied Biosystems TaqMan Probe Assay ID Rn01789993_ul 
0317o9.3 
Myc Rat NM Applied Biosystems TaqMan Probe Assay ID Rn00561507_ml 
011.603.2 
Gapdh Rat NM Applied Biosystems TaqMan Probe Assay ID Rn01775763_gl 
01Jf08.13 
~Actin Rat NM App lied Biosystems TaqMan Probe Assay ID Rn00667869 _ml 
03ll44.2 
Cris I Rat NM 5'-MT GfTGAT CGC me lGTGTI T-3' 5'-Tf AGCT AGTGTI CGC GGTGTI G-3' 
(CI.S), 66 001014258.1 
Taz, Rat NM_ 5'-CGGCTG A TI GCTGAG lGTCA-3' 5'-lCA TTC ATTCCAACA TGC CAT AG-3' 
63 001025748.1 
Pld6 Rat XM 5'-lCATCACGGACTGCG ACT A-3' 5'-GGCAMCTT AlGGfGCATGf-3' 
(MitoPLD) 22<1517.3 
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Plscr3, Rat NM 5'-GCACCA MG ATGGCAGATA-3' 5'-TAA TAGCTGTAGGGf TGGGAC C-3' 
120 001012139.2 
Myc, Rat NM 5'-GCTCTG CTC lCC GlC CT A TGf-3' 5'-ATG ACC GAGCTACTTGGAGG-3' 
123 011.603.2 
Rpsl2, Rat NM 5'-ATG GAC GfCAAC ACTGCT CT-3' 5'-ATCTCTGCGTGC TTG CAT-3' 
127 031709.3 
Gapdl\ Rat NM 5'-ClC TCTGCTCCTCCC TGf 1CT A-3' 5'-GGT MC CAG GCG TCCGAT AC-3' 
122 01Jf08.3 
f}-Actin, Rat NM 5'-CCCCATTGA ACACGGCAT T-3' 5'-GCC MC CGfGM MG ATG ACC-3' 
154 03ll44.2 
CDS-I M>use NM Applied Biosystems TaqMan Probe Assay ID Mm01208328_ml 
173370.3 
B2M M>use NM_ Applied Biosystems TaqMan Probe Assay ID Mm00437762_ml 
009735.3 
~Actin M>use NM_ Applied Biosystems TaqMan Probe Assay ID Mm00607939_sl 
007393.3 
Gapdh M>use NM_ Applied Biosystems TaqMan ProbeAssay ID Mm99999915_gl 
OOID84.2 
Crlsl, M>use NM_ 5'-GGT GfTGCACAGCATTCA-3' 5'-GCTGGA 1CT OOG TGC TIC T-3' 
107 001024385.1 
Taz, M>use NM_ 5'-CCX:: TCCATGTGAAGTGGC CATTCG3' 5'-TGG TGG TTGGAG ACG GTG ATAAGG-3' 
205 001173547.1 
Lclatl M>use NM_ 5'-AGC TGTTTG ACT <re TAG T-3' 5'-TGA TCC ATC AGA GAA ACT TA-3' 
(ALCATI) 001081071.2 
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Pld6, M>use NM_ 5'-CAC MG TTI GCC ATC GfT GA-3' 5'-GGA ACAGCC GCACATACT-3' 
(MitoPLD) 183139.2 
127 
Plsa-3, M>use NM_ 5'-ClG ATCGCC MC CTGTlC TA-3' 5'-CTI CGC GA T TCA TCC TI A GT-3' 
100 023564.4 
B2M, M>use NM_ 5'-GGf CTT TCT GGT GCT TGf CT-3' 5'-TATGTI CGGCTTCCC ATI CT-3'' 
106 009735.3 
~Actin, M>use NM_ 5'-TGTGAC GfTGAC ATC CGTM-3" 5'-GCT AGG AGCCAGAGCAGI' M-3'' 
117 007393.3 
Gapdl\ M>use NM_ 5'-MC ACTGAGCATCTC CCTCA-3" 5'-GfGGGTGCAGCG MC TTT AT-3'' 
113 OOID84.2 
1 Jl3 
Appendix C 
Other Contributions to Literature 
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